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The American University in Cairo 
DIRECT DETECTION OF MYCOBACTERIUM TUBERCULOSIS 
COMPLEX USING GOLD NANOPARTICLES 
BY: Marwa Mohsen Hussain  
Under the supervision of Prof. Hassan M. E. Azzazy 
Tuberculosis (TB) is still one of the most significant causes of morbidity and 
mortality worldwide. According to WHO, TB causes 2 million deaths and more than 
9 million new cases annually; the overwhelming majority of TB cases occur in 
developing countries where accurate diagnosis of TB remains a challenge. This work 
aims to develop a rapid nano-gold assay for specific detection of mycobacterium 
tuberculosis complex (MTBC). In the first version of the assay, DNA was extracted 
from clinical isolates grown on LJ media. 16s rDNA regions were amplified by PCR 
then the genus and species of MTB were confirmed by semi-nested PCR. Spherical 
gold nanoparticles (AuNPs; 13 nm) were synthesized by citrate reduction method of 
HAuCl4 and characterized by spectrophotometry and SEM. In the first assay, the 
16srDNA amplicons were denatured (95 
o
C, 30 s) then allowed to anneal (48 
o
C, 30 s) 
with genus- and species-specific oligotargeters in a hybridization buffer contaning 
NaCl (40 nM). This was followed by the addition of unmodified AuNPs (14 nM). In 
case of a positive specimen, the AuNPs aggregated and the solution color changed 
from red to blue. The solution retained red color in case of negative specimen. This 
assay was further optimized to specificially differentiate MTBC from other 
mycobacterial strains. In the second version of the assay, MTBC was directly detected 
in the extracted genomic DNA. Species-specific oligotargeter was added to genomic 
DNA and denatured for 3 min at 95 
o
C followed by annealing at 48 
o
C for 1 min. 
AuNPs were added and solution color changed from red to blue in case of MTBC-
positive specimens. The assay detection limit was 1 ng for PCR product and 40 ng for 
genomic DNA. The assay showed 100% sensitivity and specificity (n = 27) as 
compared with automated liquid culture system (MGIT) and semi-nested PCR. 
Following DNA extraction according to standard procedures, the assay turnaround 
time is about 1 hour. In conclusion, we have developed a nano-gold assay prototype 
for direct detection of MTBC as a low cost alternative to current amplification-based 
detection platforms. The developed assay is simple, sensitive, rapid, and shows a great 
potential in the clinical diagnosis of TB especially in developing countries with low 
resource settings.  
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CHAPTER 1: Introduction 
Tuberculosis (TB) affects one-third of the world’s population and is a serious health 
problem worldwide. In 2010, Mycobacterium tuberculosis (MTB) infected about 8.8 
millions [1]. The incidence of infection according to the World Health Organization 
(WHO) was estimated at 59 % in South East Asia, 26 % in African, 7 % in Eastern 
Mediterranean, 5 % in Europe, and 3 % in America. WHO estimated the rate of TB 
incidence to decline by < 1% per year (figure 1) [1]. TB global prevalence rate is 178 
per 100,000 whereas mortality rate is 15 per 100,000 world’s population which equals 
about 1.1 million deaths per year [1]. In Egypt, TB estimated incidence rate is 18 per 
100,000, TB prevalence rate is 28 per 100,000 and mortality rate is 0.82 per 100,000 
(figure 2) [2]. 
Several challenges hinder TB control efforts. First, TB is an airborne pathogen 
where each infected/untreated person is predicted to infect 10 - 15 persons per year. 
Second, TB also persists in the pulmonary cells in the lungs despite treatment. The 
treatment in most acute cases lasts for at least 6 months and patient compliance, 
assuming ability to tolerate side effects and cost, for this long period, is questionable 
[3-5]. This long treatment duration is mainly due to the thick mycobacterial cell wall 
structure which is rather complex and contains different long chain fatty acids (figure 
3) [6]. What is more devastating is the relatively recent evidence that BCG “Bacillus 
Calmette-Guérin”, the only available mycobacterium vaccine, has low efficacy that 
range from 0-80% depending on the immunized population [5]. The live attenuated 
vaccine lost its antigenic part region of difference (RD1) encoded proteins due to 
deletion mutation which stimulates the immunity to TB [5, 7]. This has led to 
decreased the immunization triggered and the variable efficacy range of 0% - 80% [3-
5]. Low protection, due to lack of effective prophylactic vaccines, combined with 
malnutrition in developing countries augment disease progression [3-5].  
In 2006, a strategic plan to control TB was developed jointly by WHO and the 
Stop TB organization (initiated in 2001 by different organization partnerships) [8]. 
The first goal of this strategy is to reduce TB prevalence and mortality rates by 50% 
(relative to 1990s rates) by year 2015. The second one is to get rid of TB infection as 
a public health concern by achieving an infection rate of 1 case per million by year 
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2050. All the six WHO regions are on their way to achieve 50% reduction of 
mortality and prevalence rates except for the African region. Incidence rates are also 
decreasing and are expected to meet the first goal of the Stop TB initiative in five 
WHO regions with the exception of South East Asia in which the incidence rate has 
not been reduced yet [8]. Stop TB program identified two key challenges to address 
TB diagnosis. The first challenge is improvement of current detection methods with a 
focus on developing sensitive and specific point of care testing (POCT) devices which 
could significantly contribute to TB detection. These devices are easily used, rapid, 
affordable, non- instrument dependant, and requires small volumes of reagents and 
samples. Patient’s nearby testing also supports patient compliance [9, 10].  Another 
goal is the need for rule out tests. Rule out diagnosis is required for screening and 
epidemiology purposes and reducing number of patients who require complex 
investigations thus leading to best allocation of medical resources [10].    
An ideal diagnostic assay for detection of the Mycobacterium tuberculosis 
must be sensitive with a low detection limit. It should detect Mycobacterium bacillus 
in early infection stages. It must be specific to detect the M. tuberculosis complex 
species. Besides, it should generate results fast to allow prompt initiation of treatment. 
The assay should not involve complicated procedures or sophisticated expensive 
equipments [4, 11-13]. Current TB detection methods involve smear microscopy, 
culture, and molecular techniques. Ziehl-Neelsen sputum staining depends on the 
ability of mycobacterium to resist acid de-colorization for its high mycolic acid 
content. It depends on visual microscopic examination. The method cannot detect 
some early and mid infections [14]. Culture method is considered the standard method 
for TB detection. However, it requires from 6 – 8 weeks to confirm MTB growth on 
Lowenstien Jensen (solid media) [4, 14-16]. BACTEC 460 is a
 14
CO2 modified 
Middlebrook 7H12 automated detection system.  The system detected mycobacterium 
respiration of 
14
C isotope labeled palmitic acid [15]. The main disadvantages include 
the disposal of radioactive materials, high cost, rand turnaround time of 5 – 10 days, 
and inability of this system to differentiate mycobacterium from non-mycobacterial 





Molecular methods for detection of MTB include Cobas® Amplicor. [17-19]. 
This PCR-based method detects MTB within 6.5 h with sensitivity from 91 – 100%. 
Another method, Gen-Probe® AMPLIFIED detects MTB in 3.5 h but with a reported 
86.8% sensitivity [14, 17, 19]. Although molecular detection methods show high 
sensitivity and specificity, they are expensive, time consuming, require sophisticated 
laboratory infrastructure, and highly trained personnel. None of the commercially 
available TB tests qualifies as an ideal Mycobacterium tuberculosis diagnostic method 
for TB strain identification [4, 11-13].  
  How can these limitations be circumvented using nanoparticles (NPs)? NPs 
are 1-100 nm in size (where 1 nm = 10
-9
 m) [20, 21]. They have unique and diverse 
physical and chemical properties depending on the size, shape, and materials of which 
they are synthesized. They can be designed in various shapes such as spheres, tubes, 
rods, or cubes, and can be made from different materials either inorganic elements 
such as gold, carbon and semiconductors or organic materials such as liposomes and 
dendrimers [21, 22]. Nanoparticles allow almost one-on-one interaction with 
biological molecules such as enzymes, proteins, and nucleic acids, since they are in 
the nanometer size; which significantly enhances diagnostic sensitivity [23-25]. 
Additionally, nanoparticles can act as scaffolds as they have a large volume: surface 
area ratio. This could permit functionalizing NPs with over 100 small molecules and 
of about 30 oligonucleotide strands [26].  
  Gold nanoparticles (AuNPs)  exhibit distinctive optical properties based on 
their size, shape, and surface charge [21, 23]. When an incident light, which has an 
electromagnetic oscillating field, has a wavelength smaller than the particles diameter, 
the nanoparticles induces a collective dipolar oscillation. This oscillation lies in the 
free conduction band electrons around the metal nanoparticles surface [23, 27, 28]. At 
specific frequency, the oscillation amplitude gets to the maximum. This frequency is 
known as Surface Plasmon Resonance (SPR) [27, 29-31]. Another closely related 
phenomenon is plasmon - plasmon interaction in which AuNPs aggregate together 
changing their color from red to blue. AuNPs can be induced to aggregate using 
electrolytes such as salt [23, 30]. AuNPs scattering optical properties are highly 
dependent on particle size. AuNPs 80 nm in size show light scattering 10
5
 fold higher 
than other traditional fluorescent molecules [27, 31, 32]. 
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  In this study, unmodified spherical AuNPs were employed to develop a 
prototype test to detect Mycobacterium tuberculosis complex 16s rDNA gene 
sequence amplified from clinical samples. The first version of the developed assay 
detected MTB PCR products. A second optimized version was used to directly detect 
genomic DNA in clinical specimens. The assay employs an oligo-targeter sequence 
against a conserved region in the 16s rRNA gene of TB genome. Clinical performance 
characteristics of the assay including sensitivity, specificity and detection limit were 






CHAPTER 2: Literature review 
1. Mycobacterium tuberculosis bacteriology   
Tuberculosis is an airborne respiratory disease. It spreads, in 95% of cases, through 
cough, sneezing, and sputum droplets. TB is caused by a bacterium termed 
Mycobacterium tuberculosis (MTB) which is an acid-fast beaded bacilli, non motile, 
non-spore forming, straight or slightly curved rods (figure 4) [33].  
  Microscopically, MTB smear is stained with carbol fuchsin based on its acid 
fastness, resistance of the bacilli to carbol fuchsin stain de-colorization. Upon 
examination under light microscope MTB appears as straight or slightly curved red 
rods.  
  In order to survive in harsh environmental conditions, the bacilli can build cell 
components directly from carbon and nitrogen sources (prototrophic), or use already 
synthesized carbon and nitrogen sources (heterotrophic) [33]. It is one of the slowest 
growing bacteria that have a generation time of 12 – 24 hours comparing with a 20 
min doubling time for E. coli. The genome of mycobacterium is characterized with 
high guanine/cytosine (GC) content of about 70% and its cell walls possess high lipid 
content. Mycolic acid is the most abundant lipid content in the cell wall, contributing  
to TB immune resistance [33].  
2. Mycobacterium underlying problems 
2.1. Mycobacterium species 
Mycobacterium genus includes a large diverse number of species (> 50) which can 
cause TB-like infection (non-tuberculous mycobacteria), or Mycobacterium 
tuberculosis complex (MTBC). These include: pathogenic, opportunistic, and non 
pathogenic human and animal infecting species [34, 35].  
Non-tuberculous mycobacteria are classified into rapid and slow growing 
mycobacteria. Rapid growing mycobacteria give visible colonies in less than 7 days 
while slow growing mycobacteria give visible colonies up to 8 weeks incubation [35, 
36]. They were first identified in the 1950s; however, their clinical concern emerged 
just in the last 2 decades with the rise of HIV epidemics [37]. These species are 
ubiquitous in different environmental sources such as soil, food, water, equipments, 
and aerosols. They can survive in a wide range of pHs, temperatures, and common 
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disinfectants [38, 39]. These characteristics permit nosocomial infections at high 
prevalence rates. Nevertheless, there is no evidence of non-tuberculous mycobacteria 
person-to-person transmission [35, 38]. Examples of these species are Mycobacterium 
avium, M. intracellulare, M. abscessus, M. fortuitum, M. kansasii, and M. simiae. 
Several research articles have reported pulmonary, skin and soft tissue infections, or 
disseminated diseases caused by non-tuberculous mycobacterium [35, 38, 40, 41]. 
MTBC consists of closely related species that cause TB infection to different 
hosts, these complex members are M. tuberculosis, M. bovis, M. africanum, M. 
microti, M. caprae, M. canetti, and M. pinnipedii [42, 43]. These members have DNA 
homology of about 85 – 100% [42]. MTB is the major cause of TB infection in 
humans. Animals can also get infected if contacted with infected humans [42]. M. 
bovis is the main cause of bovine TB which is due to the consumption of 
unpasteurized milk or dairy products. The established awareness campaigns against 
bovine TB have helped reducing incidence and prevalence rates in industrialized 
countries, where its prevalence is estimated as < 1% of all TB cases. It may increase 
in some populations [44]. M. africanum causes about 50% of pulmonary TB 
infections in Africa with higher estimates in HIV endemic populations [45]. M. 
microti is one of the rare mycobacterium species that was first described by Wells in 
1937 from field voles, one of the most common mammals in Europe [46-48]. Caprine 
tuberculosis is caused by Mycobacterium caprae affecting goats, cattle, and cross 
infection to humans. It is predominant in Europe and causing a major health threat in 
Spain [49, 50]. M. canetti is a rare species that has been added to the Mycobacterium 
tuberculosis complex list recently. It was isolated from a farmer infected with 
pulmonary tuberculosis [42, 51]. Finally, M. pinnipedii has been isolated from seals 
and proved experimentally to infect guinea pigs and rabbits [52]. The transmission of 
M. pinnipedii to humans was documented in an outbreak of infection [53]. 
There are differences among non-tuberculous mycobacteria and MTBC with 
regard to transmission, infection, pathogenesis, and subsequently treatment. However, 
they have similar cell morphology and microscopic examination which is the most 
common method in developing countries, cannot be used to differentiate between 
them [35]. Therefore, it is crucial to differentiate between non-tuberculous 
mycobacteria and Mycobacterium tuberculosis complex members using 
discriminative molecular techniques. 
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2.2. Mycobacterium pathogenesis 
The immune response plays a fundamental role in the defense against mycobacterium 
infection and pathogenesis. Basically, the immune response is divided into innate and 
adaptive immunity. Innate immune response is the natural immunity in which the 
immune cells face the pathogen for the first time but can eradicate it. However, 
adaptive immune response depends on previous pathogen contact information [54]. 
Tuberculosis is a latent infection in about 90% of cases without causing diseases 
while it is active in the remaining 10% of cases [33, 55-57]. It is proven that the 
transition from latent to active disease happens mainly when patients experience 
alteration in their immune system balance or became immunocompromised which is 
the reason behind the high prevalence of co-infection of HIV and TB (figure 5) [33, 
55-57]. 
Tuberculosis infection starts with the inhalation of few mycobacterial cells 
that are released from an infected patient. The first cells to interact with the intruding 
mycobacterial cells are the alveolar macrophages and epithelial cells [55, 56]. The 
interaction of the bacilli with the alveolar macrophages takes place through different 
cellular macrophage receptors. The type of receptor determines the macrophage 
response. For instance, the interaction with Fc receptors increases the release of 
reactive oxygen intermediates that degrades the bacilli and permits the fusion of 
phagosomes with the lysosomes degrading the phagosomal content, where the 
bacteria reside. Thus macrophages could kill mycobacterial cells by both the oxygen 
and nitrogen radicals and lysosomal enzymes [55, 58]. After bacterial death, 
mycobacterial antigens are presented by class II major histo-compatibility complex 
members to CD4+ T lymphocytes [55]. This allows the production of interferon-ɣ 
(IFN-γ) and interleukin-12 (IL-12) leading to macrophage activation and more bacilli 
destruction [55]. CD4+ T lymphocytes also trigger apoptosis of the infected cells to 
decrease the number of bacterial viability and mediate CD8+ T cell response. CD8+ T 
cell mediated response acts mainly through cytokine production through secreting 
IFN- γ leading to bacterial destruction, and cytolytic function through lysing infected 
cells (figure 5) [55]. 
Nevertheless, the interaction of the bacilli with different surface receptors 
leads to different pathogenesis. For instance, bacilli interaction with macrophage 
complement receptor CR3 prevents the release of reactive oxygen intermediates 
(respiratory burst). Cholesterol assists in the mycobacterium and surface receptors 
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interaction. Upon engulfment of mycobacterium in phagocytosis, phagosomes 
maturation is arrested at early stage. Phagosomes-endosomes fusion is inhibited 
preventing bacilli destruction [55, 56, 58-60]. Blocking phagosomes maturation was 
found to be contributed by the retention of a protein called Tryptophane Aspartate 
Coat Protein (TACO) [55]. TACO protein prevents further maturation. Mycobacterial 
phagosomes are also characterized by interfering with phagosomal acidification and 
inhibit endosomal pathway fusion. The limited acidification is due to the low 
concentration of late endosome proton pump V-H
+
 ATPase. Phagosmoal arrest is 
partial and some phagosomes develop to phagolysosomes (figure 6) [55, 56, 59, 60]. 
Mycobacterium bacilli secrets oxygen radical scavenger molecules such as 
lipoarabinomannan (LAM) and phenolic-glycolipid I [55]. 
Epithelial cells are also likely to be among the first cells to interact with 
mycobacterium since they are 30 times higher in number than alveolar macrophages. 
They can host and permit mycobacterium bacilli replication and are capable of 
triggering the release of IL-8 as a pro-inflammatory environment and nitric oxide 
[55].  Defensins, small endogenous antimicrobial cationic peptides which range in 
size from 30 – 50 amino acids, mediate another innate immunity response. These 
molecules can destroy microorganism’s cell components and can pass through 
cytoplasmic membrane. Defensins show a promising treatment solution; however, 
their exact anti-mycbacterial mechanism is still unknown [55].  
Since in the early infection stage T-helper 1 (Th1) mediated response such as 
IFN- γ and IL-2 showed a protective role against mycobacterium infection, late stage 
infection is characterized with down regulation of Th1 and activation of Th2 
response. Late stages show elevated IL-4 levels, transforming growth factor (TGF-β) 
(which is produced by a specialized macrophage called foamy macrophage), high 
mycobacteria cells count, interstitial fibrosis, progressive pneumonia, and subsequent 
lung granuloma. This allows the shift from the production of pro-inflammatory to 
anti-inflammatory and immunosuppressive molecules from the early to the late stage, 
respectively. Granuloma is the immune-pathology hallmark of mycobacterium 
infection. It is composed of organized spherical structure of immune cells and 
bacteria, in which the core is bacteria, macrophages, and dentritic cells (DCs) 
surrounded by T- and B- lymphocytes. Figure 7 shows the different pathogenesis 
immune factors that are involved in tuberculosis infection [57, 59, 61].  
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2.3. Mycobacterium virulence and persistence factors 
Virulence is a quantitative measure of pathogenicity [62]. Mycobacterium 
tuberculosis does not resemble other classical virulence factors such as toxins due to 
the complexity and occurrence of many factors involved in the infection. The most 
famous virulent factors are cell filtrate proteins ESAT-6 and HspX. Other virulence 
factors are categorized in table 1 [63]. 
All these virulence factors are related to exaggerating tuberculosis infection 
and persistence. These proteins, enzymes, and lipids are excellent molecular markers 
for diagnosis and already some of them are being used as antigens in vaccine 
development trials; however, more research is needed to confirm virulence role in 
infection and specificity of virulence factors to pathogenic MTB infection. 
3. Current Mycobacterium tuberculosis diagnosis methods 
Conventionally, TB diagnosis is based on Ziehl-Neelsen sputum staining using acid 
fast stain that is based on the ability of mycobacterium to resist acid de-colorization 
for its high mycolic acid content in the cell membrane (figure 4). However, this 
method cannot detect species and differentiate between tuberculous and non-
tuberculous mycobacterium. It can detect TB within 5 min for each specimen but has 
a very low sensitivity (30 – 35% positive cases). It also could not detect recent 
infections since it depends on visual microscopic examination. The detection depends 
on finding at least 1 bacillus on the microscopic slide. However, it is still the current 
frontline diagnosis method in developing countries in particular governmental 
laboratories. Culturing on selective media that allows only TB to grow is also 
challenging as it is one of the slowest growing bacteria that needs at least 21 days to 
grow. Therefore, diagnostic tests based on emerging technologies are currently being 
developed to bypass these diagnostic challenges [14]. 
3.1. Culture methods 
Culturing mycobacteria is considered as one of the less costly detection methods 
especially in screening purposes or in endemic countries. Solid and liquid medias are 
regarded as the gold standard for culturing mycobacterium; it takes from 3 to 8 weeks 
[4].  
A new approach called “BACTEC 460”, Becton Dickinson Instrument 
Systems (Franklin Lakes, US) utilized a modified Middlebrook 7H12 automated 
detection system. 
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actively labeled palmitic acid [15]. The main disadvantage of this method is the 
disposal of the radioactive waste (half life of 
14
C is 5730 years). It detects 
mycobacterium within 5 – 10 days. This method is also expensive and cannot 
differentiate between different mycobacterium species [4, 14-16]. Another diagnostic 
approach is the integration of Accuprobe (Gen-Probe, US) with BACTEC to improve 
the BACTEC efficacy. It identifies series of M. tuberculosis complex, M. avium 
complex, M. avium, M. kansasii, and M. gordonae. The Accuprobe utilizes acridinium 
ester labeled ssDNA complementary to rRNA to detect various mycobacterium 
species. This detection method uses BACTEC culture for inoculation of suspected 
samples with subsequent sonication and addition of Accuprobe to form stable DNA: 
RNA hybrids followed by signal detection using a luminometer. Although Accuprobe 
can detect mycobacterium within 2 h; the needed for expensive devices such as a 
luminometer and a sonicator may represent a difficulty in large scale implementation 
especially in developing countries [17]. 
An integrated BACTEC and MGIT 960 (Becton Dickinson, Franklin Lakes, 
US) system can test 960 samples at the same time. It has a fluorometric sensor to 
detect oxygen utilization within 8 – 15 days [14, 17, 64]. In addition, Septi-check 
AFB biphasic media BBL (Roche) was also introduced in which the samples are 
aseptically transferred to the septi-check AFB bottle that contains high CO2 
Middlebrook content media and other supplements. Septi-check AFB slide of 
Middlebrook, egg-based media, and chocolate agar is incorporated, incubated, and 
inverted on a regular basis. Average number of days of detection ranges from 21 to 28 
days [14, 65]. Another culture-based method, ESP II, is a non radioactive fully 
automated method (BD Difco, Franklin Lakes, USA). It monitors continuous pressure 
change from organism respiration. This system must be combined with other solid 
medium system to detect mycobacterium from 10 – 15 days [14]. 
3.2. Chromatography 
This is based on detecting mycolic acid, the main cell wall component, unique peaks 
pattern using high performance liquid chromatography (HPLC) that could 
differentiate between different species. The method depends on the mycolic acid 
fingerprints library which was constructed based on species dependant mycolic acid 
derivatives [14, 66]. The main limitation of this method is that it requires the 
availability of HPLC in developing countries diagnostic laboratories, also it is saving 
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time consuming method for detection. It requires culturing, extraction, derivatization, 
and HPLC analysis [14, 66]. 
3.3. Bacteriophage based method 
There are two approaches in bacteriophage based techniques; the first is based on 
infecting mycobacterium with phage D29, specific for mycobacterium, that will lead 
to insertion and subsequent amplification of phage genome in the target cells followed 
by progeny detection [14, 16, 17, 67]. If plaques form then the sample is determined 
to be positive for mycobacterium. Another approach is using luciferase reporter 
phages (LRP) allowing for luciferase enzyme transcription inside the target cells to 
detect the light produced if the sample is positive for TB when luciferin substrate is 
added [14, 16, 17, 67]. Bacteriophage D29 can be used to detect mycobacterium 
resistance depending on the ability to support phage infection in a medium containing 
rifampicin and isoniazid. Commercially available kits for those methods include 
FASTPlaque-TB® or PhageTek MB® for Biotec Laboratories Ltd, UK showing 
sensitivity of 70.3 – 75.2% and specificity of 98 – 99% [14, 17, 68]. FASTPlaque-
MDRi which is also known as FASTPlaque-TB RIF™ detects indirectly rifampicin 
susceptibility. The test requires culturing of specimens on FASTPlaque rifampicin 
containing media. It depends on the growth of rifampicin resistant mycobacterium  
[69]. The assay is inexpensive, with detection time from 1 – 2 days. Although the 
assay can detect viable mycobacterial cells it cannot detect resistance other than 
rifampicin or mycobacterium complex species that directly affects selection of 
therapeutic regimens. 
3.4. Immuno diagnostics 
To improve the sensitivity of TB detection methods, immunologic based assays have 
been developed. The potential targets for immunologic diagnostics are either through 
specific antigen, antibody, or protein detection. However, some reported TB cases are 
suffering from delayed hypersensitivity that correspondingly will affect antibody 
detection giving false negative results [14].  
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There are various antigens specific for mycbacteria that can be detected by 
enzyme linked immunosorbent assay (ELISA), indirect ELISA (iELISA), reverse 
passive haemagglutinin test, and latex agglutination test. First, enzyme linked 
immunosorbent assay is a quantitative sandwich technique in which the antigen is 
detected using specific monoclonal antibody, mAb, and then the detection signal is 
indicated with a labeled secondary antibody specific for the antigen bound mAb. Its 
sensitivity reach up to 90% which is higher than 70.3 – 75.2% sensitivity of phage 
method; however, antigen cross reactivity may occur when the antibody developed is 
not highly specific. Also, ELISA is not an easy experiment that can be done on a 
regular laboratory work in developing countries. Indirect ELISA is the same idea but 
with antigen immobilized to detect a specific antibody [14]. The most commonly used 
antigens are glycolipids, lipopolysaccharides, lipoarabinomannan, antigen 5 (38 
KDa), Esat-6 [70] and antigen 60 [14]. 
3.5. Molecular techniques 
DNA based detection methods involve three different types: amplification, 
electrophoresis, and hybridization-based techniques. Table 2 summarizes molecular 
commercial techniques.  
3.5.1. Amplification  
3.5.1.1. Target amplification 
Polymerase chain reaction (PCR) offers a rapid way to detect mycobacterium; it 
depends on selective primers design that bind to the flanking region of the target 
sequence, amplifies the sequence, and then visualizing the amplified bands using UV-
light after gel electrophoresis and ethidium bromide staining or any other detection 
methods. Commercially, there is FDA approved Cobas® Amplicor (Roche Diagnostic 
Systems), that amplify 16s rRNA gene region in mycobacterium then the biotinylated 
amplicon hybridizes with immobilized oligonucleotide on micro titer plate. The 
sensitivity range was from 91 – 100% and detection is achieved within 6.5 h [17-19]. 
Advantages of PCR includes detection within about 24 h including sample processing 
but it is still expensive and requires highly trained technicians  [14]. 
 Transcription mediated amplification (TMA) is another PCR based method but 
amplifies rRNA isothermally using the advantage that rRNA targeting shows higher 
specificity. Gen-Probe® AMPLIFIED™ (AMTB) is a FDA approved commercial kit 
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that amplifies specific rRNA by DNA transcription then detection is based on 
hybridization probe assay, Gen-probe HPA, using ssDNA (single stranded DNA) 
probe chemiluminescent labeled. When RNA – DNA hybrid is formed they are 
detected with luminometer. The test lasts for 3.5 h but with 86.8% sensitivity and with 
no control [14, 17, 19]. 
 Nucleic acid sequence based amplification (NASBA; Hain Lifescience, 
Germany) is considered as one of the TMA types. The method depends on having 
multiple copies of RNA from double stranded DNA (dsDNA) upon the action of T7 
RNA polymerase [71]. Commercially, an integrated NASBA-DNA strip is done 
through magnetic bead capturing isolation and NASBA amplification of 23S rRNA 
followed by automated reverse hybridization. The assay is reliable and rapid, with 
specificity and sensitivity of 100% and 92%, respectively [17]. 
3.5.1.2. Probe amplification 
Probe amplification method such as ligase chain reaction (LCR) is an assay that 
ligates 2 primers designed for detection after hybridization with the target, it depends 
on the presence of DNA ligase enzyme and nucleotides in the reaction. LCx MTB 
Abbot is used to detect mycobacterium within 6 hours with sensitivity and specificity 
of 74% and 98%, respectively. The main drawbacks are the need for trained personnel 
and high cost which limit its wide application [14, 71-74].  
 A semi-quantitative isothermal amplification via strand displacement 
amplification (SDA) is also developed. The method implies primer/probe 
amplification technique rather than target amplification based in which an initial 
target denaturation took place then each of the primer and the probe bind on the 
complementary target strand close to each other. The probe designed to have a 
restriction endonuclease site. First stage, DNA polymerase deficient exo-nuclease 
activity polymerizes by adding nucleotides extending the primer; 2’ deoxyadenosine 
5’-O-(1-thiotriphosphate), dATPaS, a modified nucleotide, is added in the reaction to 
be incorporated displacing probes. 
  Displaced probes bind to complementary primers allowing their extension 
with DNA polymerase. Second stage, the newly synthesized DNA : probe digested 
with restriction endonuclease enzyme; only the probe strand will be cut because of the 
incorporated dATPaS resulting in a nick formation which is extended by DNA 
polymerase again at the 3’ end of the nick displacing the downstream strand. The 
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process continues for further exponential amplification process. Amplified segments 
can be detected using chemiluminescence hybridization system or integrated into any 
detection system. DProbe Tec ET assay utilizes a detection system based on 
fluorescence energy transfer. The method offers a sample free contamination system 
as the reaction is done in a single tube within 4 h; it has not been approved by FDA 
yet [14, 17, 19, 71]. 
3.5.1.3. Signal amplification 
 Amplification of the signal is done through a dual function probe that detects the 
target sequence and a branched amplifier. This system shows high sensitivity and 
detection signal. However, it is not available commercially [14]. 
3.5.2. Electrophoresis based methods  
Restriction fragment length polymorphism (RFLP) is mainly used to detect mutations 
abolishing or creating restriction sites. Mycobacterium RFLP was used to detect 
mycobacterium species of amplified gene encoding heat shock protein. The test is 
reliable, cost effective, and results are ready within a day [75, 76]. 
Single stranded conformational polymorphism (SSCP) is employed to detect 
resistant mycobacterium having SNPs affecting ssDNA conformation. Resistant MTB 
ssDNA exhibits slightly different motility on polyacrylamide gel electrophoresis that 
can be distinguished from that of the reference strain [77]. 
3.5.3. Hybridization based methods  
3.5.3.1. Line probe technology 
This is based on amplifying specific sequences with biotinylated primers followed by 
reverse hybridization with immobilized probes in a parallel way on a simple strip 
having the advantage of banding pattern based colorimetric detection with an 
automated system with turnaround time within about 5 h. Two systems have been 
developed based on such technology: Inno Lipa Mycobacteria v2 (Innogenetics, 
Belgium) and Genotype mycobacterium (Hain LifeScience, Germany) [17, 19].  
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Inno Lipa Mycobacteria v2 is a strip test that identifies the most frequent 17 
mycobacterium strains clinically isolated based on differences in 16s and 23s rRNA 
gene. The test showed 100% for both specificity and sensitivity with cross reaction 
between 2 rare mycobacterium species [17, 19]. Genotype mycobacterium is another 
assay available as two commercial kits: Genotype MTBC identifies Mycobacterium 
tuberculosis complex members based on gyrB gene polymorphism and Genotype 
mycobacterium CM for common species of mycobacterium based on 23S rDNA 
variations. Genotype MTBC failed to identify 3 species, Mycobacterium tuberculosis 
is one of them, due to typical hybridization pattern observed; all of them are easy to 
perform in standard laboratories. Sensitivity and specificity compared to sequencing 
for Genotype CM is 92.4% [17, 19]. 
3.5.3.2. DNA chips hybridization 
DNA microarray is a hybridization technique using fluorescent labeled amplicons; 
detection is based on hybridization pattern and signal intensity. This method permits 
detection of large number of samples at the same time within 2 h; it is an expensive 
method [17]. CombiChip Mycobacteria (Geneln, Pusan,South Korea) used probes for 
16s rRNA gene to differentiate between species [78]. 
3.6. Sequencing 
Sequencing is the gold standard method in diagnosis either with sequencing directly 
or initial PCR followed with amplicon sequencing with automated sequencer [17]. 
Sequencing methods include manual sequencing of Maxam-Gilbert chemical 
sequencing, Sanger sequencing, and Pyrosequencing. The later technique detects 
pyrophosphate PPi release upon step by step nucleic acid synthesis [17]. Nonetheless, 
sequencing is not an economic choice for routine diagnosis. The most common target 
gene for sequencing is 16s rRNA because this gene encodes for both highly conserved 
sequences for genus identification and different species identification [17].  
 The MicroSeq System (Applied Biosystems, CA) is a commercial PCR based 
sequencing of 16s rRNA gene which showed reliable results [79]. Pyrosequencing™ 
(Biotage, Uppsala, Sweden) targeted about 30 bp of a highly variable sequence region 
A of 16s rRNA gene to differentiate between mycobacterium species [79].  
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4. Recent Mycobacterium tuberculosis trends in diagnostic approaches  
Loop mediated isothermal amplification (LAMP) was developed to detect members of 
the mycobacterium complex using IS6110 repetitive insertion gene as a target. The 
test showed 20 times more efficiency than the conventional IS6110 test [80]. 
A micro fluidic biosensor has been developed for environmental screening of 
TB. The culture based chip is based on differentiation of TB from other bacteria based 
on the lipophilic property of the TB using paraffin. Incubated mycobacteria samples 
preferred adherence to hydrophobic surfaces such as paraffin due to mycolic acid 
content. Selective culturing of mycobacterium allowed their detection 
microscopically. The test is still a prototype [81]. 
A novel multi-channel piezoelectric quartz crystal (MSPQC) sensor system 
was developed for detection of rapid growth of Mycobacterium tuberculosis using an 
automatic continuous monitoring system. The system used to detect TB based on 
measurements of NH3 and CO2, the volatile metabolic products generated during 
growth, diffusing into the KOH absorbing solution, resulting in the change of 
conductance of the absorbing solution detected by the MSPQC accurately [82]. 
A gene chip has been developed to detect mycobacterium using the membrane 
oligonucleotide array method [83]. 
A number of nano-diagnostic assays have been developed for detection of TB. 
In 2006, Baptista et al. developed gold nanoparticles modified with probe specific to 
mycobacterium RNA polymerase β subunit gene. The test detects Mycobacterium 
tuberculosis in clinical sputum samples but after initial PCR round. The test detected 
up to 0.75 µg of total DNA in 2 h time [84]. In 2009, Soo et al. used gold 
nanoparticles probes modified with thiol to identify Mycobacterium tuberculosis 
complex. They used two probes that are specific to part in IS6110 and Rv3618 DNA 
for targeting Mycobacterium tuberculosis complex and Mycobacterium tuberculosis, 
respectively. The test showed 96.6% sensitivity and 98.9% specificity for detection of 
Mycobacterium tuberculosis complex and 94.7% sensitivity and 99.6% specificity for 
detection of Mycobacterium tuberculosis; 600 samples were tested. The assay offered 
simple, rapid, cost-effective and accurate detection but used 2 PCR rounds to detect 
the targets and 1 day turnover [85]. Liandris et al. used DNA-gold nanoparticles 
probes specific to mycobacterium 16s – 23s internal transcribed spacer (ITS). Test 
detection limit was 18.75 ng DNA with 2 days turnaround time without the need for 
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DNA amplification [86]. Costa et al. developed another gold nanoprobes based 
mycobacteria test to detect Mycobacterium bovis, Mycobacterium tuberculosis, and 
Mycobacterium tuberculosis complex. Probes were specific to amplified gyrB DNA 
fragment of mycobacteria [87].  
In 2010, Gazouli et al. employed a different nanotechnology approach. They 
developed magnetic beads conjugated with streptavidin and genus specific probe and 
fluorescent semiconductor quantum dots (QDs) conjugated with streptavidin and 
species specific probe to detect TB unamplified DNA. The probes were designed to 
target 23s rRNA gene part and IS6110 transposase. The assay is based on a sandwich 
hybridization method and used DNA isolated from formalin fixed paraffin embedded 
tissues (FFPE), bronchoalveolar lavage, and feces. The detection limit was shown to 
be up to 12.5 ng TB DNA in the reaction [88]. Li et al. developed a membrane 
transfer-based colorimetric mycobacterial DNA detection using alkaline phosphatase 
modified gold nanoparticles. Test detection limit was 0.23 pmol/L for 16s rDNA PCR 
product [89].  
5. Gold Nanoparticles 
5.1. Historic Background 
Gold nanoparticles were shown to be extracted in the 5
th
 millennium B.C near 
Bulgaria and in 1200-1300 B.C in China and Egypt, extraction reached around 10 
tons gold per year [90, 91]. They used gold colloid in manufacturing ruby class 
colored ceramics and the most famous example is the Lycurgus cup. Then in 1618, 
the first book on colloidal gold was published by Doctor Francisci Antonii. In this 
book, the author described how to use the curative power of the soluble gold to treat 
and diagnose many diseases which had been illustrated with practical cases [90]. In 
1857, Michael Faraday gave the birth to nanotechnology by discovering the reason 
behind different colors of gold nanoparticles and the reversible color change upon 





 century, an enormous number of reviews, experimental articles, and books have 
been published describing various synthesis methods, different physical and chemical 
properties, and fascinating biological applications of gold nanoparticles [28, 90]. 
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5.2. AuNPs structure  
Gold nanoparticles have several types; the two main types are the spherical AuNPs 
and nanoshells. Spherical AuNPs sizes range from 0.8 to 250 nm (generally from 1 – 
100 nm) and have a UV-visible absorption spectrum at the visible region from 400 - 
700 nm [20, 23, 28, 30]. Nanoshells are composed of gold metal as a thin shell layer 
surrounding a dielectric core of an inert material such as silica. Varying in the 
core/shell thickness alters the physicochemical properties of the nanoshell [23, 93]. 
These nanoshells range in size from 10-300 nm [23, 28].   
5.3. AuNPs synthesis and Bio-conjugation 
5.3.1. Synthesis 
Generally, there are 2 main approaches in synthesizing nanoparticles: top-down or 
bottom-up approach. Top-down strategy involves the use of bulk materials to generate 
smaller nanoparticles through physical methods (mechanical or photolithography); 
bottom-up approach starts with molecular component of the nanoparticles, allowing 
for nucleation and growth of nanoparticles to the desired size through chemical 
methods [94].  
  The most common approach is the bottom up strategy through chemical 
methods. This method involves dissolving metal salt in an appropriate solvent 
followed by metal reduction to its zero valence state. The critical problem is that these 
metallic atoms in solution tend to aggregate. This could be achieved through using 
capping agents. These capping agents function through coating the surface of NPs, 
blocking its growth beyond the required size, and stabilizing the colloid formed in the 
solvent used. AuNP shape and size control is achieved through cautious selection of 
reaction conditions: time, temperature, and selection of reducing and capping agents 
[30, 94, 95].  
5.3.1.1. Citrate reduction method  
Citrate reduction method was introduced in 1951 by Turkevitch and is considered as 
one of the famous and conventional AuNPs preparation methods. The concept behind 
this method is that Au
III




Cl4) is reduced to 
Au
0
 using reducing agent trisodium citrate [90, 91, 96, 97]. This method is used up till 
now as it is advantageous in the ease of replacing citrate shell with other ligands 
allowing for better stabilization and size control [90, 91, 97].  
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5.3.1.2. Shiffrin – Brust method  
Shiffrin – Brust method was introduced in 1993 by Giersig and Mulvaney, they 
introduced the possibility of stabilizing AuNPs using different chain length of 
alkanethiols through the strong gold – sulfur bond. The concept here is that HAu IIICl4 
is reduced by sodium borohydride (NaBH4) in an organic solvent (toluene) and in the 
presence of thiol capping ligand (dodecanethiol (DDT)), also tetraoctylammonium 
bromide (TOAB) is used as a phase – transfer reagent [90, 97, 98].  This method is 
advantageous if functionalizing AuNPs surface with thiol ligands is required. 
Thiolated ligands are specific to biomolecules such as oligonucleotides or peptides 
[90, 91, 97]. The method synthesizes hydrophobic or also called monolayer protected 
clusters (MPCs) AuNPs [97]. 
5.3.2. Bio-conjugation 
Functionalization methods involve modification of AuNPs based on the application. 
Unmodified AuNPs can be used directly for label free colorimetric detection methods. 
AuNPs can be functionalized with varied biomolecules either directly to their surfaces 
through covalent bonds (Au-S) or indirectly (specific recognition such as Au-S-
antigen antibody or Au-S-biotin avidin). This is achieved by using ligands containing 
a sulfur group (such as thiolate or disulfide). This method offers higher stability of 
ligands with AuNPs and can be used for detecting antigens, antibodies, DNA, 
carbohydrates, proteins, peptides, or any biomolecules of interest while withstanding 
harsh experimental conditions [28, 30, 99, 100]. 
5.4. Physicochemical properties 
5.4.1. Absorbance properties 
AuNPs behave as other metal nanoparticles when exposed to light due to their shared 
photophysical properties. Their specific scattered light behavior is responsible for 
their intense red color. The incident light has an electromagnetic oscillating field. 
When this electromagnetic field has a wavelength smaller than the particles diameter, 
the nanoparticles induces a collective dipolar oscillation in the free conduction band 
electrons around the metal nanoparticles surface [23, 27, 28]. At specific frequency, 
the oscillation amplitude gets to the maximum. This frequency is known as Surface 
Plasmon Resonance (SPR) (figure 8) [27, 29-31]. The SPR is the reason behind the 
enhanced optical scattering and absorbance properties in the visible frequency range 
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(400 – 700 nm) and this can be identified using a spectrophotometer.  Gold and silver 
nanoparticles (noble metals) specifically have stronger SPR bands compared to non 
plasmonic nanoparticles. Additionally, the SPR band wavelength and intensity are 
affected by the metal type, nanoparticles shape and structure, particle size, and the 
surrounding medium dielectric constant. For instance, increasing the AuNPs size 
causes red shift in the SPR wavelength [27, 29]. Another closely related phenomenon 
is plasmon - plasmon interaction in which AuNPs colloid aggregate together changing 
their color from red to blue. AuNPs can be induced for aggregation using electrolytes 
such as salt. Accordingly, this phenomenon is used in biomolecule detection and 
molecular diagnosis [23, 30].  
5.4.2. Scattering properties  
Light scattering occurs when AuNPs emit photons as a result of electron oscillation. 
These emitted photons can be either at the same frequency of the incident light and in 
this case are called “Mie or Rayleigh scattering” or at shifted frequency and in this 
case are called Surface Enhanced Raman scattering” (SERS) (figure 9). This energy 
shift is a result of molecular motion [27, 31]. The scattering properties of AuNPs 
make them a powerful tool in cell imaging techniques instead of traditional 
fluorescent dyes. This is because AuNPs have higher fluorescence and a stable signal. 
AuNPs scattering optical properties are highly dependent on particle size, they 
potentiate with larger particle size. For instance, 80 nm AuNPs in size show light 
scattering 10
5
 fold higher than other traditional fluorescent molecules [27, 31, 32].  
5.5. Detection methods 
5.5.1. Non functionalized AuNPs 
This method involves the use of unmodified AuNPs based on the electrostatic 
adsorption between citrate coated AuNPs and ssDNA leading to AuNP stabilization 
preventing its induced aggregation. This stabilization results from the weaker force of 
repulsion between nitrogenous bases of ssDNA and negative citrate coat of gold 
nanoparticles than that of dsDNA and AuNPs. This is because ssDNA can uncoil 
sufficiently causing adsorption between AuNPs and the exposed nitrogenous bases of 
the uncoiled ssDNA while dsDNA has a stable double helix structure exposing a 
negatively charged phosphate backbone. In the presence of a DNA target and enough 
salt concentration, ssDNA will complement with its DNA target preventing the 
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stabilization of gold nanoparticles allowing for its salt induced aggregation and 
consequent color change from red to blue. This is considered as the simplest method 
of ligand functionalization and is used mainly in label free colorimetric detection 
methods for dsDNA (figure 10) [28, 30, 99, 101, 102]. 
5.5.2. Functionalized AuNPs 
5.5.2.1. Non cross-linking  
In non cross-linking functionalization, AuNPs are linked to ssDNA for detecting 
ssDNA targets in the presence of salt allowing for gold colloid aggregation [103]. 
Biomolecules are linked to gold nanoparticles either directly to its surface through 
covalent bonds (Au-S) or indirectly (specific recognition such as Au-S-
antigen/antibody or Au-S-biotin/avidin). This is achieved by using ligand containing 
sulfur group (such as thiolate or disulfide) [28, 90]. This functionalization method 
offers a higher stability for ligands with AuNPs and can be used for detecting 
antigens, antibodies, DNA, carbohydrates, proteins, peptides, or any biomolecules of 
interest as it can withstand relatively harsh reaction conditions (figure 10) [28, 30, 99, 
100]. 
5.5.2.2. Cross linking  
Another functionalization approach had first been reported in 1996 by Mirkin et al. 
and Alivisatos et al., is the cross-linking method. This method depends on cross 
linking gold nanoparticles with – DNA conjugates together in the presence of a target 
of interest leading to a visual AuNPs color change [104, 105]. In cross linking, two 
sets of AuNPs get functionalized with two different probes complementary to the two 
target ends of a ssDNA target in a design of either head-to-head or heat-to-tail [104]. 
Mirkin et al. developed a different approach using a DNA linker complementary to 
AuNPs conjugate probes allowing bio-conjugation of AuNPs with different probes at 
a time [105]. Table 3 shows various detection methods for detection of AuNPs. 
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CHAPTER 3: Materials and Methods 
1. Mycobacteria strains  
For reference strains, two mycobacterium reference strains of Mycobacterium H37Ra 
and Mycobacterium smegmatis were cultivated and refreshed on Lowenstein Jensen 
solid media. Reference strains were obtained from Misr University for Science and 
Technology (MUST), faculty of pharmacy, Microbiology department. Media were 
supplied and prepared according to the manufacturer’s protocol (Oxoid Ltd, 
Cambridge, UK) [106]. Middlebrook 7H9 broth media supplemented with Tween 80 
and glycerol were obtained from BD Difco/ BBL (Becton, Dickinson and Company, 
Franklin Lakes, USA) [107].  
For clinical strains, 11 anonymous clinical DNA samples isolated from TB 
patients were obtained from Misr University for Science and Technology (MUST), 
faculty of pharmacy, Microbiology department. An additional 14 clinical DNA 
samples isolated from TB patients were obtained from the U.S. Naval Medical 
Research Unit No.3 (NAMRU-3) (table 4). 
2. Mycobacterial strains processing 
2.1. Sample treatment 
All mycobacteria samples were processed for DNA extraction according to 
established methods [108]. 
For reference strains, Cells were harvested from liquid media by 
centrifugation of each 250 mL aliquot at 2500 x g for 15 min at room temperature 
(Sigma Aldrich,Germany). Culture supernatant was decanted and cell pellets 
collected. Each cell pellet was re-suspended in 25 mL Tris-EDTA buffer (TE) 
(Promega, Wisconsin, USA) pH 8.0 and cells were centrifuged and harvested. All cell 
pellets were stored at -20 °C for a minimum of 4 h. This resulted in weakening of cell 
envelop and more efficient cell lysis [108]. 
2.2. DNA Extraction  
For reference strains, Cell pellets were thawed and suspended in 5 mL TE buffer pH 
8.0. An equal volume (5 mL) of chloroform / methanol (C/M) 2: 1 (Promega) were 
added and mixed for 5 min. This allowed for more efficient cell lysis as it removes 
most of the cell wall lipids. The suspension was centrifuged at 2,500 x g for 20 min at 
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room temperature. The mycobacteria formed a firm band at the organic-aqueous 
interface. So, tightly bacterial band was left in the tube and both the organic and 
aqueous layers were decanted. To remove the remaining of the organic solvent, the 
uncapped tube containing the depilated cells were put in water bath at 55 °C for 10 – 
15 min. 5 mL of TE buffer pH 8.0 were added and the cells were suspended by 
vigorous vortex. 0.5 mL of 1M Tris-HCl (0.1 of the final volume) pH 9.0 was added 
to increase the pH of the cell suspension. 55 µL Lysozyme (10 mg/µL) (Promega) 
added to a final concentration of 100 µg/mL and incubated at 37 °C for 12-16 h. To 
remove cell proteins and contaminants, 0.5 mL 10% SDS (Promega) (0.1 volume of 
the final volume) and 60 µL of proteniase K (0.01 volume of the final volume) 
(Promega) were added. The extract was mixed by inverting the tubes up and down 
several times and incubated at 55 °C for 3 h.  
Proteins were extracted from the resulting suspension by adding an equal 
volume of phenol / choloroform / isoamyl (P/C/I) 25:24:1 (Sigma Aldrich) and gentle 
shaking for 30 min followed by centrifugation at 12,000 x g for 30 min at room 
temperature. The aqueous layer was gently transferred to a sterile tube. To re- extract 
the aqueous layer, an equal volume of C/I 24:1 was added for 5 min with gentle 
rocking and repeat the step of centrifugation. The aqueous layer transferred again to a 
sterile tube. To precipitate TB genomic DNA, 0.1 of the total volume of 3 M sodium 
acetate (Sigma), pH 5.2, and 1 of the total volume of isopropanol (Sigma) were added. 
Tubes were inverted slowly to mix and stored at 4 °C for 1 h. The solution was 
centrifuged at 12,000 x g for 30 min at room temperature to pellet the DNA. The 
supernatant was discarded and the pellet washed with cold 70% ethanol. The DNA 
pellet re-suspended in nuclease-free water [108].For digestion of isolated DNA, the 
DNA obtained was digested with a restriction enzyme Bam HI (Promega) according 
to the manufacturer’s instruction by incubation at 37 °C for 1 hour followed by 
deactivation at 65 °C for 15 min. Five units  Bam HI were required for each 1µg/µL 
DNA.  
2.3. DNA quantification 
DNA was diluted and absorbance measured at 260 and 280 nm using a double beam 
spectrophotometer (Shimadzu, UV-3600, Kyoto, Japan). DNA concentration was 
calculated using the formula:  
DNA Concentration (µg/mL) = (A260)(50 µg/mL)(dilution factor) 
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3. Amplification of 16s rDNA gene segment 
3.1. Primers design and analysis 
Genomic sequences of Mycobacterium H37Ra and Mycobacterium smegmatis were 
obtained from NCBI genome database with (Gene Bank accession numbers: 
CP000611 and CP000480, respectively). PCR primers were designed using Invitrogen 
Vector NTI advance software using the obtained genomic sequences. For analysis, 
primers selected were investigated to avoid primer dimers, hairpin loops, 
palindromes, repeats, and asses their specificity for 16s rDNA. Primers were 
synthesized by Sigma (BIONEER, California, USA).  
3.2. PCR 
PCR was done using PCR master mix (Promega) and  Bam HI digested DNA. BamHI 
restriction enzyme was selected based on the absence of a restriction site within the 
specified region. 5% Dimethyl sulfoxide (DMSO, Promega) was added in the master 
mix. DMSO was added to facilitate strand separation as it disrupts strong base pairing 
[109] due to the high GC content of mycobacterium [33]. For 50 µL PCR reaction, 25 
µL PCR Master Mix 2X were added. 2.5 µL of 10 µM of each forward and reverse 
primer were added. 5 µL of DNA template and 15 µL nuclease-free water were 
added. PCR was done in 30 cycles: initial denaturation at 95 °C for 2 min, 
denaturation at 95 °C for 30 s, annealing temperature at 46 °C for 1 min, extension at 
72 °C for 45 s, and final extension at 72 °C for 2 min in a thermal cycler (MyCycler, 
Bio-Rad, California, USA).  
3.3. Semi nested PCR 
Semi-nested PCR was done on purified amplicons. Genus and species semi-nested 
PCR were done in two separate reactions for each sample. Genus semi-nested PCR 
was done using the forward PCR primer and genus oligo-targeter as the reverse 
primer. In species semi-nested PCR, species oligo-targeter was used as the forward 
primer with the PCR reverse primer. This was done with master mix 2X (Promega) 
without the need for restriction digestion using PCR amplicons obtained previously as 
a DNA target. For 25 µL PCR reaction, 12.5 µL PCR Master Mix 2X were added. 1.5 
µL of 10 µM of each forward and reverse primer were added. 5 µL of DNA template 
and 4.5 µL nuclease-free water were added. Semi-nested PCR was done in 25 cycles: 
initial denaturation at 95 °C for 2 min, denaturation at 95 °C for 30 s, annealing 
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temperature at 50 °C for genus and 52 °C for species for 1 min, extension at 72 °C for 
45 s, and final extension at 72 °C for 2 min in a thermal cycler (Bio-Rad). Melting 
temperature for primers was calculated using the formula: 
Tm= 64.9 °C +41°C x (yG + zC – 16.4) / N 
Where N is the number of primer bases 
3.4. PCR amplicons: Purification, visualization, and quantification  
PCR products were purified using QIAGEN PCR clean up kit (Purified PCR was 
separated using gel electrophoresis (Biorad) on 0.7% agarose gel, semi-nested on 1% 
agarose gel (Promega), were stained with ethidium bromide (Promega) and visualized 
using UV light. Photos were taken, analyzed and quantified using LabImage 1D 
software (Kapelan Bio-Imaging Solutions, Leipzig, Germany). 
Purified PCR amplicon was diluted and absorbance measured at 260 and 280 
nm using a double beam spectrophotometer (Shimadzu).     
4. Gold nanoparticles synthesis 
Spherical gold colloid was prepared using citrate reduction method [110]. Briefly, an 
aqueous solution of hydrogen tetrachloroaurate (III) (HAuCl4.3H2O) (1mM) (99.99% 
Sigma Aldrich, Germany) was brought to reflux and stirred followed by a quick 
addition of 1% trisodium citrate solution. Solution color changed from yellow to wine 
red. The solution was then refluxed for an additional 15 min and left to cool at room 
temperature. The resulted spherical gold nanoparticles were filtered using a 0.45 µm 
pore size acetate filter (Sigma), and transferred into a clean storage glass bottle. Gold 
colloid absorption peak was scanned by spectrophotometer in the range of 400 – 700 
nm with a concentration of 14 nM.  
5. TB nano-gold assay 
5.1. Oligo-targeters selection 
Hybridization oligo-targeters of genus and species were selected from previous 
literature based on a conserved 16s rDNA gene part and synthesized by BIONEER 
[111]. Oligo-targeters were analyzed for specificity using NCBI Blastn tools and 
Invitrogen Vector NTI advance 11 software (Life technologies, New York, USA).  
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5.2. Detection of TB PCR and genomic DNA   
5.2.1. Detection of PCR product 
TB hybridization was optimized using different concentrations of NaCl (Sigma), 
phosphate buffered saline pH 7.4 (Sigma), phosphate buffered saline 0.3M NaCl 
(Sigma), PCR hybridization buffer, and Tris – HCl (Sigma). Genus and species oligo-
targeters were used in different concentration ratios: 1:1, 1:2, and 1:3. Also 
hybridization with species oligo-targeter only was done.  
Detection of PCR product was done by adding 44 mM NaCl, 2.5 µL 1M Tris – 
HCl, 0.02 µM oligo-targeters and 5 µL PCR product followed by denaturation at 
95°C for 30 s and annealing at 48°C for 30 s. Then 30 µL gold colloid 13nm ± 2 was 
added. Absorption peak for positive and negative was scanned by spectrophotometer 
in the range of 400 – 700 nm. 
5.2.2. Detection of genomic DNA 
Detection of genomic DNA was studied with addition of DMSO 2 – 5% (Promega). 
Several physical methods for shearing DNA such as vortex of DNA, vortex with glass 
beads, and DNA extraction with SiO2 were tested. Chemical (enzymatic) digestion of 
DNA was done with Hind III restriction enzyme (Promega).  
Detection of digested DNA was done by adding 10 mM NaCl, 0.083 µM 
oligo-targeters, and 1 µL DNA sample digested (containing the specified RE buffer E; 
Promega) followed by denaturation at 95 °C for 3 min and annealing at 48 °C for 1 
min then 15 µL of gold nanoparticles was added. 
Detection of genomic DNA of 25 clinical strains was done using genomic 
DNA digestion by Bam HI restriction endonuclease (Promega). The assay was done 
by adding 2.5 µL Tris  HCl, 44 mM NaCl (0.5 M), 1 µL species oligo-targeter (1µM), 
4 µL digested genomic DNA, and 3.54 µL H2O. The mixture was denatured at 95 °C 
for 3 min and annealed at 46°C for 1 min, then 30 µL AuNPs was added. Positive and 
negative samples were scanned with a spectrophotometer in the range of 400 – 700 
nm. 
5.3. Detection limit of TB nano-gold assay  
Nano-gold assay was done as previously mentioned with different DNA 
concentrations. A two fold serial dilution was done for PCR products of 
Mycobacterium H37Ra as a reference strain and one clinical strain for a DNA range 
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from 14.1 ng to 0.44 ng. Dilutions were tested with nano-gold assay as described 
above. 
A two fold serial dilution was done for digested genomic DNA of a clinical 
strain of Mycobacterium tuberculosis complex (range from 40 ng to 10 ng). Dilutions 
were tested with nano-gold assay as described above.  
The difference of detection limit between PCR product and digested genomic 
DNA was analyzed by calculating their corresponding molar concentrations according 
to the following formula:  




CHAPTER 4: Results 
1. DNA extraction 
DNA extracted from reference and clinical strains was visualized clearly on 0.7% 
agarose gel electrophoresis (figure 11) and absorbance measured at 260 and 280 nm 
showed high purity and concentration of DNA.  
2. Amplification of 16s rDNA gene part 
2.1. Primers design and analysis 
Using Invitrogen Vector NTI advance software, the best primer pair was selected 
from a list of possible primers based on lowest melting difference between the two 
primers. Primers obtained that can amplify 16s rDNA gene part are TBF: 
ACATGCAAGTCGAACGGAAAGG and TBR: 
CCTCCTGATATCTGCGCATTCCAC (table 5). For analysis, forward primer (TBF) 
was found to be free of palindromes, repeats, and  hairpin loops with dG value (dG 
value indicates the spontaneity of a reaction to occur, negative value indicates double 
stranded PCR product) - 38.6 Kcal/mol while it has 3 dimers with dG values of - 2.0, - 
1.8, and - 0.4 Kcal/mol. Reverse primer (TBR) was found to be free of repeats and  
hairpin loops with 2 palindromes at bases 7 and 13, with dG value of - 41.7 Kcal/mol 
while it has 2 dimers with dG values of -8.8 and -2.1 Kcal/mol. 
2.2. PCR  
PCR for reference and 2 clinical strains resulted in 16s rDNA target amplification and 
clear bands were visualized on 0.7% agarose gel electrophoresis. Bands’ molecular 
weight was calculated using Lab Image 1D software and found to be in a range from 
650 – 790 bp (figure 12). Total amount of DNA from purified PCR products were 
found to be around 130 ng with no protein or RNA contamination.   
PCR for DNA of 9 anonymous clinical strains resulted in 16s rDNA target 
amplification and clear bands were visualized on 0.7% agarose gel electrophoresis. 
Bands’ molecular weight was calculated using Lab Image 1D software and found to 
be in a range from 709 - 736 bp as shown in figure 13. 
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2.3. Semi nested PCR 
Semi- nested PCR for reference and 2 clinical strains resulted in genus and species 
specific regions amplification confirming genus and species oligo-targeters 
specificity, respectively. Mycobacterium smegmatis showed no band for species. 
Bands’ molecular weight was calculated using Lab Image 1D software. Genus semi-
nested PCR resulted in bands length range from 167 – 186 bp. Species semi-nested 
PCR resulted in bands length range from 173 – 199 bp (figure 14).  
Semi-nested PCR for 9 anonymous clinical strains DNA resulted in genus and 
species specific regions amplification confirming that the strains belong to 
Mycobacterium tuberculosis complex. Bands’ molecular weight was calculated using 
Lab Image 1D software. Genus semi-nested PCR resulted in bands length range from 
145 – 221 bp. Species semi-nested PCR resulted in bands length range from 168 – 
259 bp (figure 15).  
3. Gold nanoparticles synthesis 
Spherical gold colloid absorbance peak was found to be at 520 nm with a diameter of 
13 nm ± 2 (14 nM) (figure 16). 
4. TB nano-gold assay  
4.1. Oligo-targeters selection 
Selected genus oligo-targeter GR: AAAGTGCTTGTTGCGCTGTT and species 
oligo-targeter SF: ACCACAAGACATGCATCCCG were used in semi nested PCR 
and AuNPs detection. Nucleotide Blast of both oligo-targeters showed 40 – 50 
alignment score (table 6). Genus oligo-targeter (100 blast hits) showed 100% query 
coverage for all mycobacteria sequences (figure 17) while species oligo-targeter (274 
blast hits) showed 100% query coverage for only Mycobacterium tuberculosis 
complex members (figure 18).  
4.2. Detection of TB PCR and Genomic DNA   
Two versions of the nano-gold assay were developed. The first assay detected 
mycobacterium genus from other bacteria. The second nano-gold method 
differentiated M. tuberculosis complex from mycobacterium genus. Both nano-gold 




4.2.1. Detection of TB PCR amplicon 
PCR amplicons did not hybridize to target in presence of NaCl in different 
concentrations (30 mM – 70 mM), phosphate buffered saline (PBS) and PBS with 
0.3M NaCl. Hybridization occurred with PCR buffer and NaCl with Tris – HCl. 
Genus and species oligo-targeters used in concentration ratio 1:1 showed positive 
results for all TB strains (figure 19), 1:2 and 1:3 ratios differentiated in 
Mycobacterium smegmatis (violet) from other mycobacterium (blue) (figure 20 and 
figure 21, respectively). The use of species oligo-targeter only resulted in a negative 
result (red color) for Mycobacterium smegmatis and positive color (blue) for other 
Mycobacterium tuberculosis complex (figure 22). Also, other bacterial DNA such as 
E. coli and Staphylococcus aureus showed negative results. Absorption peak for 
negative was at 525 nm and for positive was shifted to 550 nm (figure 23). 
4.2.2. Detection of genomic DNA 
Addition of DMSO 2 – 5% did not show hybridization of target to oligo-targeters. 
Also shearing of DNA with all physical methods was not sufficient to anneal DNA 
with oligo-targeters. Chemical digestion of DNA with Hind III restriction enzyme 
showed positive results. The first version of the assay differentiated mycobacteria 
genus from other bacteria using genus and species oligo-targeters (figure 24). The 
second developed assay detected M. tuberculosis complex using species oligo-targeter 
only (figure 25). 
Detection of Bam HI genomic digested DNA for 25 clinical strains showed all 
strains as positive while control and Mycobacterium smegmatis digested genomic 
DNA remained negative (figure 26 and figure 27). Absorption peak for negative was 
at 525nm and for positive was shifted to 610 nm (figure 28). 
4.3. Detection limit of TB nanogold assay 
Amplified DNA detection limit was done for Mycobacterium H37Ra and clinical 
strain D and calculated to be 1 ng (figure 29).  
Genomic digested DNA detection limit was done for Mycobacterium 
tuberculosis complex clinical strain number 3 and calculated to be 40 ng (figure 30). 
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CHAPTER 5: Discussion  
This is the first study to use unmodified AuNPs in diagnosing MTBC. The assay 
employs genus and species specific oligo-targeters sequence (each is 20 nucleotides) 
that recognizes TB 16s ribosomal DNA (rDNA) gene (table 6) [111]. 16s rDNA has a 
highly conserved sequence among mycobacteria genus along with hyper-variable 
regions that differentiate the species of the same genus [112]. These oligo-targeters 
were designed based on sequence analysis of various mycobacterium species [111].  
  To confirm oligo-targeters specificity, the two oligo-targeters were blasted on 
Blastn NCBI database. Genus oligo-targeter showed 100% similarity to blast hits (no 
gaps) with all mycobacterium genus (100 hits). Alignment E value was 5e-04 (the 
lower the E value, or closer to zero, the more significant) (figure 17). Species oligo-
targeter showed 100% similarity to blast hits (no gaps) with all Mycobacterium 
tuberculosis complex (274 hits). Alignment E value was 5e-04 (figure 18).  
  Using Vector NTI software, the two oligo-targeters were aligned on 
Mycobacterium smegmatis and Mycobacterium H37Ra complete genome of about 
4411 Kb. PCR primers were designed for the selected 16s rDNA gene part. The 
resulted primer pairs were analyzed using the same software to select the lowest 
melting temperature difference (table 5). Selected PCR primers were blasted on NCBI 
Blastn to confirm specificity to all mycobacterium strains. Primers showed 100% 
identity with all mycobacterium.  
  First, a TB nano-gold assay was developed to detect Mycobacterium 
tuberculosis complex after PCR amplification. This assay was modified and 
optimized to directly detect TB using digested genomic DNA thus eliminating the 
need for PCR and reducing time and cost needed for diagnosis. The nano-gold TB 
detection experimental part is of two versions. The first version of the nano-gold TB 
assay was developed to distinguish mycobacterium genus from other bacteria using 
spherical AuNPs. The second version was optimized to detect and distinguish 
Mycobacterium tuberculosis complex from mycobacterium genus. Both nano-gold 
assays detected TB from PCR amplicons and genomic DNA.  
  Unidentified mycobacterium specimens were detected first by semi-nested 
PCR before AuNPs detection. Genus and species semi-nested PCR used PCR 
amplicons as a target DNA and employed genus and species oligo-targeters as reverse 
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and forward primers, respectively. Another aim for semi-nested PCR was to prove the 
specificity of the selected oligo-targeters. To confirm that genus oligo-targeter is 
specific for mycobacterium genus and species oligo-targeter is specific for M. 
tuberculosis complex.  
  The two reference strains selected for detection were Mycobacterium 
smegmatis as a negative control and Mycobacterium H37Ra as a positive control. 
Both M. smegmatis and M. H37Ra belong to the genus mycobacterium but only M. 
H37Ra belongs to M. tuberculosis complex. Mycobacterium H37Rv was not selected 
as it is a pathogenic strain. Reference strains were processed for DNA extraction. The 
most critical step in DNA extraction is cell wall lysis. The reason behind this is that 
the complex structure of mycobacterial cell wall and its high lipid content (figure 3) 
[6, 33]. The addition of chloroform / methanol removed a considerable quantity of the 
cell wall lipids. However, more research is warranted to optimize TB DNA extraction 
via a simple and fast process.  
  Before PCR, restriction digestion was used to allow the primers to access their 
hybridization targets. Analysis of the restriction sites was done by Vector NTI 
advance 11 software. Bam HI restriction enzyme was selected to digest TB DNA 
based on the absence of a recognition site in the selected amplified region (16s 
rDNA). DMSO was added to facilitate TB DNA strand separation [109] which is 
relatively difficult due to the high GC content of mycobacterium DNA [33]. 
Following PCR, purification was done to remove PCR buffer and excess primers that 
could affect the assay. Only thirteen PCR cycles were sufficient to exponentially 
amplify specific 16s rDNA gene segment in a range from 650 – 790 bp (figure 12).  
  For the anonymous clinical samples, PCR was done after genomic Bam HI 
restriction digestion and addition of 5% DMSO. The exponential amplification of 16s 
rDNA gene segment resulted in clear amplified specific bands in a range from 709 - 
736 bp (figure 13). The difference in bands length is attributed to sequence variation 
or mutations in 16s rDNA.  
Genus and species semi-nested PCR was then done to verify that the selected 
oligo-targeters targets’ are within the amplified region. Semi-nested PCR resulted in 
amplified genus and species specific bands in length range 167 – 186 bp and 173 – 
199 bp, respectively. Species semi-nested PCR of M. smegmatis showed no band. 
Species amplicons were slightly larger in length confirming specificity (figure 14).  
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To verify that the unidentified 9 specimens belong to MTBC. Semi-nested 
PCR was done as described previously. Genus and species semi-nested PCR resulted 
in amplified specific genus and species specific bands in length range 145 – 221 bp 
and 168 – 259 bp, respectively (figure 15). 
  Gold nanoparticles were synthesized to be within a size range of 13 ± 2 nm 
(14 nM). Spherical AuNPs were synthesized using trisodium citrate as the reducing 
agent. Citrate reduction resulted in nanoparticles with a negative surface charge [110]. 
Synthesized particles showed an absorbance peak at 520 nm (figure 16). Double 
stranded DNA detection is based on ssDNA oligo-targeters electrostatic adsorption on 
AuNPs surface. TB DNA extracted from clinical samples was denatured and 
permitted to anneal with 16s rDNA specific genus and species oligo-targeters in a 
suitable hybridization buffer and spherical AuNPs were then added. In the absence of 
the DNA target, oligo-targeters remain free. Upon addition of AuNPs, oligo-targeters 
uncoil sufficiently and their nitrogenous bases get adsorbed on AuNPs negative 
surface.  Repulsion arises between exposed negatively charged phosphate backbone 
of adsorbed oligo-targeters. This allows dispersion and stabilization of AuNPs 
preventing their electrolyte induced aggregation. In the presence of the DNA target, 
each ssDNA of oligo-targeter will be hybridized to its complementary DNA strand. 
Upon addition of AuNPs, AuNPs aggregation occurs due to the presence of salt in the 
hybridization buffer. Negatively surface charged AuNPs interact with salt cation 
causing their aggregation. Induced aggregation leads to a shift in AuNPs absorbance 
peak from 520 nm to about 600 nm concurrent with a visual color change from red to 
blue (figure 31) [102, 113].  
  The nano-gold assay is affected by five factors: oligo-targeter concentration 
and length, salt concentration, AuNPs concentration, shape and size, 
denaturation/annealing temperature, and the hybridization buffer [102]. These factors 
were optimized for detection of Mycobacterium tuberculosis complex.  The constant 
parameters in this study were the oligo-targeters length and AuNPs shape and 
diameter.  
  The first version of nano-gold assay was developed to detect mycobacterium 
genus from other bacteria. First, the color change between a negative control and a 
positive sample was adjusted using different salt, oligo-targeter and AuNPs 
concentrations. A problem was encountered with the hybridization of PCR amplicons 
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with oligo-targeters due to the high GC content [33]. Different hybridization buffers 
were used such as NaCl at different concentrations, PBS or PBS containing 0.3M 
NaCl. Hybridization occurred also using PCR buffer, proving that Tris base buffering 
capacity was required for mycobacterium hybridization. As PCR buffer has high 
chloride content providing unclear AuNPs visual difference, NaCl with Tris – HCl 
was used for hybridization. Since our target DNA is double stranded DNA, genus and 
species oligo-targeters used in concentration ratio 1:1. This showed all TB strains as a 
positive (including M. smegmatis, M. H37Ra, and 2 mycobacterium clinical strains) 
differentiating mycobacterium genus from other bacteria, E. coli and Staph. aureus, 
(figure 19). 
  The second version of nano-gold assay was optimized to detect and 
distinguish M. tuberculosis complex from mycobacterium genus. During the previous 
reaction, M. smegmatis amplified DNA was hybridized only with the genus oligo-
targeter. Only half of the NPs aggregated shifting the visually observed color to 
positive. To circumvent this difficulty, lower genus oligo-targeter and higher species 
oligo-targeter concentration ratios were used. Genus and species oligo-targeters were 
used in concentration ratios of 1:2 (figure 20) and 1:3. A ratio of 1:3 improved M. 
smegmatis color change from reddish violet to violet and M. H37Ra and 
mycobacterium clinical strains as clear blue (figure 21). Moreover, using of species 
oligo-targeter only resulted in discriminative visual color difference. The assay 
showed the control and M. smegmatis as a negative (red) and M. H37Ra and 
mycobacterium 2 clinical strains as positives (blue) (figure 22). Positive samples 
showed an absorbance peak shift from 525 nm in negative samples to 550 nm broad 
band (figure 23). This is the first time to report the use of a single oligo-targeter in 
unmodified AuNPs detection method for TB detection.  
  Previous literature explained that target DNA is denatured completely and the 
two complementary oligo-targeters hybridize with the two strands. This contradicts 
with the results because the use of a single oligo-targeter would allow the genus oligo-
targeter to hybridize with one target strand leaving the other to stabilize the AuNPs. 
The possible explanation is that long (target) ssDNA do not stabilize AuNPs. Another 
probable explanation is that the target DNA denatures and/or anneals in a similar way 
to a replication bubble. Then each oligo-targeter of them anneal. This would allow 
one oligo-targeter to anneal with the target in the replication bubble with complete 
AuNPs aggregation (figure 32).  
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  Detection limit for PCR products was about 1 ng DNA (figure 29) which is the 
lowest compared to other reported nanoparticles based mycobacterium diagnosis 
assays. Baptista et al. test detected up to 0.75 µg [84], Soo et al. detected 0.5 pmol of 
PCR product (about 40 ng) [85] and Liandris et al. employed the use of DNA - gold 
nanoparticles conjugates with a detection limit of 18.75 ng [86]. Finally, Li et al. 
developed a membrane transfer-based colorimetric mycobacterial DNA with a 
detection limit of 0.23 pmol/L [89]. 
  To eliminate the need for PCR and save time in diagnosis, genomic DNA is 
used as a target for the previous optimized two nano-gold assays. As mycobacterium 
genomic DNA is GC rich, it was difficult to denature and hybridize. The addition of 
DMSO 2 – 5 % did not allow for hybridization but facilitated the aggregation of 
AuNPs. The promising solution was to shear mycobacterium DNA. Physical methods 
of shearing include: vortex, vortex with glass beads, and sucking DNA in a syringe 
needle. All these physical methods failed to shear mycobacterium genomic DNA. 
Another method of DNA extraction using silicon dioxide was proven to shear 
bacterial DNA [114]. The method was tried on both E. coli and mycobacterium DNA. 
It resulted in complete shearing of E. coli DNA while mycobacterium DNA did not 
shear. The other way of DNA shearing is chemical digestion via the use of restriction 
endonucleases. Restriction digestion of mycobacterium DNA with optimization of salt 
concentration allowed for oligo-targeter – target hybridization directly from genomic 
DNA (figure 24 and figure 25).  
Detection of digested genomic DNA using AuNPs was done and resulted in a 
sharp positive color change for all 25 Mycobacterium tuberculosis clinical strains 
(figure 26 and figure 27). This result confirms that the assay detected Mycobacterium 
tuberculosis complex using unmodified AuNPs with a single oligo-targeter. A UV-
visible absorbance peak of a negative sample was at 525 nm while for positive 
digested genomic DNA samples showed UV-visible absorbance broad peak shift to 
610 nm (figure 28).  
  Detection limit for digested genomic DNA was 40 ng DNA (figure 30). The 
difference of detection limit between PCR product and digested genomic DNA is 
attributed to the higher copy number of target DNA in PCR amplicons than in 
genomic DNA. To proof that, the molar concentrations for both the PCR product and 
genomic DNA were calculated (table 7). Molar concentration of PCR product was 
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12440 pM while of genomic DNA was 3.49 pM. The wide variation between the 
molar concentrations of the PCR product and genomic DNA could explain the 
difference in detection limit. Another factor is the restriction digestion time, longer 
















CHAPTER 6: Conclusions and Future Prospects 
  Since the identification of Mycobacterium tuberculosis in 1882 by Robert 
Koch, TB diagnosis has been challenging. Airborne mode of transmission, lung 
persistence, lack of rapid, sensitive and cost effective identification as well as the 
declined efficacy of the solely existing vaccine, BCG, has encumbered MTBC 
detection. In this research, unmodified spherical AuNPs were used for direct detection 
Mycobacterium tuberculosis complex DNA after PCR amplification. A second 
version of the assay detected TB DNA directly after restriction digestion of TB 
genomic DNA isolated from clinical specimens using a single oligo-targeter that 
recognizes 16s rDNA gene segment. The assay detection limit was 1 ng for PCR 
product and 40 ng for digested genomic DNA. The assay showed 100% sensitivity 
and 100% specificity as compared with bacterial culture method (gold standard) and 
semi-nested PCR. The assay turnaround time is about 1 hour including sample 
digestion and detection of extracted DNA. The TB nano-gold assay is inexpensive 
and does not require sophisticated instruments or expensive reagents. Consequently, 
this assay is a promising candidate as a frontline test for diagnosing Mycobacterium 
tuberculosis complex. After optimization, it can replace the Ziehl-Neelsen staining 
detection method in developing countries.  
  Several developments of the developed prototype include further testing using 
non-tuberculous species to further confirm specificity such as M. avium, M. 
intracellulare and M. abscessus. A multi copy specific conserved TB DNA sequence 
will be targeted to improve the assay detection limit. Due to mycobacterium high lipid 
contained cell wall DNA extraction is a time consuming process (1-2 days). Thus, a 
second improvement will involve the development of rapid DNA extraction 
procedures to extract TB DNA directly from sputum samples. To avoid personal bias 
that may be encountered during visual detection of color change, a small reader will 
be produced that detects color change spectrophotometrically. Another version of the 
TB nano-gold assay will be developed and optimized for direct detection of MDR and 





CHAPTER 7: Tables 
Table 1. Mycobacterium cell virulence factors exaggerating tuberculosis 







1. Cell filtrate proteins  such as ESAT -6, 
CFP-10 and HspX 
2. Cell surface components such as LAM, 







1. Fatty acid and Lipid metabolism such as 
IcI 
2. Amino acid synthesis genes such as LeuD 
3. Oxidative stress proteins and anaerobic 




1. Response regulator such as PhoP 
2. Sigma factors such as Sigma A 
[63] 
ESAT-6: Early secretory antigenic target (6kDa). CF-10: Culture filtrate protein. HspX: Heat shock 
protein. LAM: Lipoarabinomannan glycolipid. Erp: Surface located protein.  Mas: Mycocerosic acid 
synthase. ICI: Isocitratelyase enzyme. LeuD: Isopropylmalate Isomerase enzyme. KatG: 






















Main advantage Main disadvantage Ref. 
Cobas® Amplicor  PCR Target: 16s rDNA  
Detects in 6.5 h 
Sensitivity 91 %  
• Requires PCR 
• Trained personnel 
• Expensive  





TMA Target: 16s rRNA  
Detects in 3.5 h 
Sensitivity 86.8 %  
• Requires PCR & 
Luminometer 
• Trained personnel 
• Expensive 









Detects in 5 h 
Sensitivity 100 % 
 
• Requires PCR 
• Trained personnel 
• Expensive  
• Depends on culturing 
[17, 
19] 
Genotype MTBC  Line probe 
hybridization 
Target: gyrB gene 
Detection time N/A  
Sensitivity N/A 
 
• Failed to identify 3 
species, including M. 
tuberculosis  
• Depends on culturing 
[17, 
19] 
MicroSeq System  Sequencing  Target: 16s rDNA 




• Requires PCR 
• Requires sequencer 
• Trained personnel 
• Expensive  
• Depends on culturing 
[17] 
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SNP: Single nucleotide polymorphism. KCNE1: Potassium voltage-gated channel subfamily E member 1. 
a
 May involve PCR 
b
 May involve RT-PCR  























clinical strains  
14 + + 
Anonymous TB clinical strains 11 + + 
Mycobacterium H37Ra 1 + + 
Mycobacterium smegmatis 1 + – 
Other bacterial strains 
(Staphylococcus aureus and E. 
coli) 








Table 5. PCR primers used for amplification of TB 16s rDNA 
TBF: Mycobacterium forward primer 















































  M. H37Ra:  
 (1473211-1473860) 
 
  M. smegmatis:       




Table 6. Selected mycobacterium 16s rDNA specific oligo-targeters  
TBG: Mycobacterium genus oligo-targeter 
TBS: Mycobacterium tuberculosis complex species oligo-targeter 
 
 
Oligonucleotide designed sequences Blast 
hits 
Alignment identity 
TBG: TTGTCGCGTTGTTCGTGAAA 100 100% for different mycobacteria 
species 
TBS: ACCACAAGACATGCATCCCG 274 100% for mycobacteria strains 
















PCR product 0.7 5.65 12440 1 ng 
Genomic 
DNA 
4411 10 3.49 
40 ng 
DNA Concentration (µg/mL) = (A260)(50 µg/mL)(dilution factor)  




















CHAPTER 8: Figures 
 
Figure 1. WHO Tuberculosis incidence estimates in 2010  
The figure shows five discriminatory legend colors for different incidence ranges. The 
highest range is more than or equal to 300 per 100 000 population per year which is 
reported in South Africa. The lowest range is from 0 – 24 per 100 000 population per 
year which is observed in Egypt (18 per 100 000 population), Saudi Arabia (18 per 
100 000 population), Canada (4.7 per 100 000 population), and United States (4.1 per 














Figure 2. TB incidence, prevalence, and mortality rates in Egypt 
Egypt TB estimated incidence rate was 18, prevalence rate was 28, and mortality rate 























Figure 3. Schematic representation of mycobacterial cell wall 
Mycobacterium cell wall is composed of three layers. The first is cytoplasmic 
membrane layer. Inner membrane is linked to the cell wall core layer. This stratum 
contains three different covalently linked structures: peptidoglycan (grey), 
arabinogalactan (blue) and mycolic acids (green). The peptidoglycan is attached to 
arabinogalactan via a disaccharide phosphate linker. The arabinogalactan is a 
branched-chain polysaccharide. The hexaarabinofuranosyl termini of arabinogalactan 
are linked to mycolic acids through ester bonds. The covalent linkage of mycolic 
acids results in a hydrophobic layer. Mycolic acid layer is also called mycomembrane. 
The outer part of the mycomembrane contains a variety of free lipids, such as 
phthiocerol dimycocerosates, phenolic glycolipids, dimycolyltrehalose, sulpholipids 
and phosphatidylinositol mannosides. Most of these lipids are specific for 
mycobacteria. The outer-most layer, which is commonly called the capsule, mainly 














Figure 4. Acid fast stain of mycobacterium cells 
Mycobacterium tuberculosis smear is stained with carbol fuchsin based on its acid 
fastness upon examination under light microscope; it appears as straight or slightly 
curved red rods. The staining requires floating of the suspected slide in carbol fuchsin 
stain with continues heat exposure for 5 min after stain boiling. De-colorization of 
slide using 1% acid alchohol. Counter staining occur with methylene blue for 30 s.  
Rinse with water and allowed for microscopic examination. The detection depends on 
detecting at least a bacillus in the microscopic slide. It is the current detection method 

















Figure 5.  Mycobacterium tuberculosis infection: Three outcomes 
Human infection of Mycobacterium tuberculosis has three main mechanisms. A) 
Spontaneous healing of infected human is postulated with a minute percentage. B) 
Direct development of an active disease infection usually occurs in 
immunocompromised patients. C) Containment of mycobacterium bacilli in about 90 
% of patients resulting in latent infection. Latent infection develops into active disease 
upon reactivation. At the site of infection (granuloma), T cells and infected 
macrophages controls the infection with the production of interferon- γ and tumour 
necrosis factor-α. Activated infected macrophages allow the production of 
antimicrobial agents such as reactive nitrogen and oxygen intermediates. IFN- γ: 
Interferon- γ. TNF-α: Tumour necrosis factor-α. RNI: Reactive nitrogen 













Figure 6. The intracellular pathogenesis of mycobacterium infection 
The interaction of the bacilli with a variety of surface receptors leads to different 
pathogenesis. Cholesterol assists in the mycobacterium and surface receptors 
interaction. Upon engulfment of mycobacterium in phagocytosis, phagosomes 
maturation is arrested at early stage. Fusion of phagosomes with endososomes is 
inhibiting preventing bacilli destruction. Blocking phagosomes maturation was found 
to be contributed by the retention of TACO protein. TACO prevents further 
phagosomes maturation. Mycobacterial phagosomes interfere with phagosomal 
acidification and inhibit endosomal pathway fusion. The limited acidification is due to 
the low concentration of late endosome proton pump V-H
+
 ATPase. Phagosmoal 
arrest is partial and some phagosomes develop to phagolysosomes. MR: Mannose 
Receptor. CR: Complement Receptor. FcR: Receptor for the constant Fragment of 
immunoglobulin. SPR: Surfactant Protein Receptor. TLR: Toll-like receptor. TACO: 
tryptophane aspartate-containing coat protein. LAMP-1: Lysosomal-Associated 
Membrane Protein 1. V–H+ATPase: vacuolar ATP-dependent proton pump. Rab7: 
Member of the small GTPase family. LBPA: Lysobiphosphatic acid. Figure 













Figure 7. Immune factors affected by tuberculosis infection 
Pathogenesis of mycobacterium causes shift from the production of pro-inflammatory 
to anti-inflammatory and immunosuppressive molecules. In the early infection stage, 
a protective role against mycobacterium infection showed T-helper 1 mediated 
response such as IFN- γ and IL-2. However, late infection stage is characterized with 
down regulation of Th1 and activation of Th2 response. Progressive infection stage 
shows elevated IL-4 levels and TGF-β leading to high mycobacteria cells count, 
interstitial fibrosis, progressive pneumonia, and subsequent lung granuloma. Figure 
















Figure 8. Surface Plasmon Resonance (SPR) of gold nanoparticles 
When a light hits AuNPs, light has an electromagnetic field of a wavelength larger 
than AuNPs diameter, the nanoparticles induces a collective dipolar oscillation for the 
free conduction band electrons around the metal nanoparticles surface. At a specific 
frequency, the oscillation amplitude gets to a maximum. This frequency is known as 
















Figure 9. Optical properties of gold nanoparticles 
Gold nanoparticles interaction with light resulted in absorption and scattering 
properties. As a result of electron oscillation, gold nanoparticles emit photons in the 
form of scattered light. These emitted photons can be either at the same frequency of 
the incident light and termed “Mie or Rayleigh scattering” or at a shifted frequency 
from the incident light and called “Surface Enhanced Raman scattering”. Figure 
















Figure 10. Different methods for functionalization of gold nanoparticles 
Gold nanoparticles are functionalized in different techniques to varied biological 
biomolecules. A: Negatively charged biological molecules are adsorbed to gold 
nanoparticles directly to its surface. B: Biological molecules are linked indirectly 
through specific recognition such as Au-S-antigen antibody. C: Biological molecules 
are linked indirectly through specific recognition through Au-S-avidin biotin. D: 











Figure 11. Agarose gel electrophoresis of extracted genomic mycobacterial DNA 
Mycobacterium genomic DNA extracted was separated using gel electrophoresis on 
1% agarose gel, stained with ethidium bromide, and visualized using UV light. Lane 
1: Mycobacterium smegmatis genomic DNA. Lane 2: Mycobacterium H37Ra 











Figure 12. Agarose gel electrophoresis of 16s rDNA amplified from mycobacteria 
reference and clinical strains 
Mycobacteria 16s rDNA PCR amplicons for 2 reference and 2 clinical strains. 
Amplicons were separated using gel electrophoresis on 0.7% agarose gel, stained with 
ethidium bromide, and visualized using UV light. PCR resulted in about 700 bp 
specific amplicons. Figure of 16s rDNA PCR amplicons is a LabImage 1D software 
processed photo. Lane 1: 10,000 bp DNA ladder. Lane 2: Mycobacterium smegmatis 
650 bp. Lane 3: Mycobacterium H37Ra 700 bp. Lane 4: Mycobacterium tuberculosis 







Figure 13. Agarose gel electrophoresis of 16s rDNA amplified from unidentified 
mycobacterium clinical strains 
Mycobacteria 16s rDNA PCR amplicons for 9 unidentified clinical strains. Amplicons 
were separated using gel electrophoresis on 0.7% agarose gel, stained with ethidium 
bromide, and visualized using UV light. PCR resulted in about 700 bp specific 
amplicons. Figure of 16s rDNA PCR amplicon is a LabImage 1D software processed 
photo. Lane 1: 100 bp DNA ladder. Lane 2: strain 1 (709 bp). Lane 3: strain 2 (727 
bp). Lane 4: strain 3 (736 bp). Lane 5: strain 4 (736 bp). Lane 6: strain 5 (727 bp). 
Lane 7: strain 6 (736 bp). Lane 8: strain 7 (718 bp). Lane 9: strain 8 (736 bp). Lane 







Figure 14. Agarose gel electrophoresis of genus- and species-specific amplicons 
prepared by semi-nested PCR from mycobacteria reference and clinical strains  
Genus and species semi- nested PCR amplicons for 2 reference and 2 clinical 
mycobacteria strains. Amplicons were separated using gel electrophoresis on 1% 
agarose gel, stained with ethidium bromide, and visualized using UV light. Semi-
nested PCR resulted in genus and species specific regions amplified confirming genus 
and species oligo-targeters specificity, respectively. Figure of semi-nested PCR is a 
LabImage 1D software processed photo. Lane 1: 100 bp DNA ladder. Lane 2: 
Mycobacterium smegmatis species (no band). Lane 3: Mycobacterium smegmatis 
genus (173 bp). Lane 4: Mycobacterium H37Ra genus (173 bp). Lane 5: 
Mycobacterium H37Ra species (199 bp). Lane 6: Mycobacterium tuberculosis clinical 
strain B genus (186 bp). Lane 7: Mycobacterium tuberculosis clinical strain B species 
(193 bp). Lane 8: Mycobacterium tuberculosis clinical strain D genus (167 bp). Lane 





Figure 15. Agarose gel electrophoresis of genus- and species-specific amplicons 
prepared by semi-nested PCR from unidentified mycobacteria clinical strains 
Genus and species semi- nested PCR amplicons for 9 unidentified mycobacteria 
clinical strains. Amplicons were separated using gel electrophoresis on 1% agarose 
gel, stained with ethidium bromide, and visualized using UV light. Semi-nested PCR 
resulted in genus and species specific regions amplified confirming that these 9 
mycobacteria strains belong to M. tuberculosis complex. Figure of semi-nested PCR 
is a LabImage 1D software processed photo. Lane 1: 100 bp DNA ladder. Lane 2: 
strain 1 genus (161 bp). Lane 3: strain 1 species (189 bp). Lane 4: strain 2 genus (168 
bp). Lane 5: strain 2 species (178 bp). Lane 6: strain 3 genus (154 bp). Lane 7: strain 
3 species (168 bp). Lane 8: strain 4 genus (145 bp). Lane 9: strain 4 species (171 bp). 
Lane 10: strain 5 genus (160 bp). Lane 11: 100 bp DNA ladder. Lane 12: strain 5 
species (186 bp). Lane 13: strain 6 genus (177 bp). Lane 14: strain 6 species (211 bp). 
Lane 15: strain 7 genus (198 bp). Lane 16: strain 7 species (230 bp). Lane 17: strain 8 
genus (225 bp). Lane 18: strain 8 species (249 bp). Lane 19: strain 9 genus (221 bp). 





Figure 16. Absorption spectra of synthesized spherical unmodified gold 
nanoparticles 
Spherical gold nanoparticles colloid prepared using citrate reduction method. The 
method employs the reduction of HAuCl4. Synthesized AuNPs have negative surface 
charges with a diameter of 13 nm ± 2 and a concentration of 14 nM. Synthesized 














Figure 17. NCBI nucleotide blast results of mycobacterium genus-specific oligo-
targeter  
Genus oligo-targeter was selected from previous literature based on a conserved 16s 
rDNA gene segment. The genus mycobacterium oligo-targeter NCBI blastn resulted 
in (100 blast hits) 100% query coverage for all mycobacteria sequences, confirming 









Figure 18. NCBI nucleotide blast results of M. tuberculosis complex-specific 
oligo-targeter 
Species oligo-targeter was selected from previous literature based on a conserved 16s 
rDNA gene segment. The Mycobacterium tuberculosis complex oligo-targeter NCBI 
blastn resulted in (274 blast hits) 100% query coverage for all M. tuberculosis 











Figure 19. Use of AuNPs for detection of PCR amplicons to differentiate 
mycobacterium genus from other bacteria 
Detection of amplified 16s rDNA PCR amplicons using synthesized AuNPs. Genus 
and species oligo-targeters used in a concentration ratio of 1:1. PCR amplicons were 
denatured (95 °C, 30 s) and allowed to anneal (48 °C, 30 s) with genus and species 
specific oligo-targeters. The hybridization buffer contained NaCl and Tris – HCl. In 
positive mycobacteria specimen, genus and species oligo-targeters hybridized with 
their specific regions. AuNPs aggregated change their visual color from red to blue. In 
negative specimen, genus and species oligo-targeters stabilized AuNPs preventing 
their aggregation. This first version of the assay differentiated mycobacterium genus 
from other bacteria. Negative control (left, red) with non specific DNA (Staph. 


















Figure 20. Use of AuNPs for detection of PCR amplicons to differentiate MBTC 
from mycobacterium genus 
Detection of amplified 16s rDNA PCR amplicons using synthesized AuNPs. Genus 
and species oligo-targeters used in a concentration ratio of 1:2. PCR amplicons were 
denatured (95 °C, 30 s) and allowed to anneal (48 °C, 30 s) with genus and species 
specific oligo-targeters. The hybridization buffer contained NaCl and Tris – HCl. In 
positive mycobacteria specimen, genus and species oligo-targeters hybridized with 
their specific regions. AuNPs aggregated change their visual color from red to blue. In 
negative specimen, genus and species oligo-targeters stabilized AuNPs preventing 
their aggregation. This second version of the assay developed to differentiate M. 
tuberculosis complex from mycobacterium genus. The use of higher concentration of 
species oligo-targeter prevents hybridization with the target DNA in a M. smegmatis 
specimen. Un-hybridized species oligo-targeter stabilized AuNPs preventing their 
aggregation. (1) Negative control with non specific DNA. (2) M. smegmatis amplified 
DNA (-ve MTBC). (3) M. H37Ra amplified DNA (+ve MBTC). (4) M. tuberculosis 
clinical strain amplified DNA (+ve MBTC). (5) AuNPs M. tuberculosis clinical strain 


















Figure 21. Use of AuNPs for detection of PCR amplicons to differentiate MBTC 
from mycobacterium genus 
Detection of amplified 16s rDNA PCR amplicons using synthesized AuNPs. Genus 
and species oligo-targeters used in a concentration ratio of 1:3. PCR amplicons were 
denatured (95 °C, 30 s) and allowed to anneal (48 °C, 30 s) with genus and species 
specific oligo-targeters. The hybridization buffer contained NaCl and Tris – HCl. In 
positive mycobacteria specimen, genus and species oligo-targeters hybridized with 
their specific regions. AuNPs aggregated change their visual color from red to blue. In 
negative specimen, genus and species oligo-targeters stabilized AuNPs preventing 
their aggregation. This second version of the assay differentiated M. tuberculosis 
complex from mycobacterium genus, showed positive results for M. tuberculosis 
strains only. The use of higher concentration of species oligo-targeter prevents their 
hybridization with the target DNA even more in a M. smegmatis specimen. Un-
hybridized species oligo-targeter stabilized more AuNPs preventing their aggregation. 
(1) Negative control with non specific DNA. (2) M. smegmatis amplified DNA (-ve 
MTBC). (3) M. H37Ra amplified DNA (+ve MBTC). (4) M. tuberculosis clinical 
strain amplified DNA (+ve MBTC). (5) AuNPs M. tuberculosis clinical strain 















Figure 22. Use of AuNPs for detection of PCR amplicons to differentiate MBTC 
from mycobacterium genus 
Detection of amplified 16s rDNA PCR amplicons using synthesized AuNPs using 
species oligo-targeter only. PCR amplicons were denatured (95 °C, 30 s) and allowed 
to anneal (48 °C, 30 s) with species specific oligo-targeter. The hybridization buffer 
contained NaCl and Tris – HCl. In positive mycobacteria specimen, species oligo-
targeter hybridized with its specific region. AuNPs aggregated change their visual 
color from red to blue. In negative specimen, species oligo-targeter stabilized AuNPs 
preventing their aggregation. This second version of the assay showed positive results 
for M. tuberculosis strains only, differentiated M. tuberculosis complex from 
mycobacterium genus. The use of only species oligo-targeter prevents hybridization 
with the target DNA in a M. smegmatis specimen. Unhybridized species oligo-targeter 
stabilized most of AuNPs preventing their aggregation. (1) Negative control with non 
specific DNA. (2) M. smegmatis amplified DNA (-ve MTBC). (3) M. H37Ra 
amplified DNA (+ve MBTC). (4) M. tuberculosis clinical strain amplified DNA (+ve 





















Figure 23. Absorption spectra of AuNPs used for detection of TB 16s rDNA 
amplicons  
The suspected sample denatured and annealed with oligo-targeters in the presence of 
salt. AuNPs were added for detection. In negative specimen, the target DNA did not 
hybridize with specific oligo-targeters. Oligo-targeters uncoil sufficiently to get 
adsorbed on negatively surface charged AuNPs through nitrogenous bases. AuNPs 
stabilization occurs in the presence of salt, preventing their aggregation and 
absorbance peak shift. In positive specimens, the target DNA hybridized with specific 
oligo-targeters. AuNPs aggregated change their visual color from red to blue shifting 
























Figure 24. Use of AuNPs for detection of digested genomic DNA to differentiate 
mycobacterium genus from other bacteria 
Genomic DNA was denatured (95 °C, 3 min) and allowed to anneal (48 °C, 1 min) 
with genus and species specific oligo-targeters. The hybridization buffer contained 
NaCl and Tris – HCl. In positive mycobacteria specimen, genus and species oligo-
targeters hybridized with their specific regions. AuNPs aggregated changing solution 
color from red to blue. In negative specimen, genus and species oligo-targeters 
stabilized AuNPs preventing their aggregation. This first version of the assay 
differentiated mycobacterium genus from other bacteria. (1) Negative control with 






















Figure 25. Use of AuNPs for detection of digested genomic DNA to differentiate 
MTBC from mycobacterium genus  
Genomic DNA was denatured (95 °C, 3 min) and allowed to anneal (48 °C, 1 min) 
with species specific oligo-targeter. The hybridization buffer contained NaCl and Tris 
– HCl. In positive mycobacteria specimen, species oligo-targeter hybridized with its 
specific region. AuNPs aggregated change their visual color from red to blue. In 
negative specimen, species oligo-targeter stabilized AuNPs preventing their 
aggregation. This second version of the assay showed positive results for M. 
tuberculosis strains only, differentiated M. tuberculosis complex from mycobacterium 
genus. (1) Negative control with non specific DNA. (2) M. smegmatis digested 



















Figure 26. Use of AuNPs for detection of Bam HI digested genomic DNA for 9 M. 
tuberculosis clinical specimens 
AuNPs detection of Bam HI digested genomic DNA using species oligo-targeter only. 
Genomic DNA was denatured (95 °C, 3 min) and allowed to anneal (48 °C, 1 min) 
with species specific oligo-targeter. This second version of the assay showed positive 
results for M. tuberculosis strains. Negative control (far left tube, red). Tubes (1 to 9): 




















Figure 27. Confirmation of AuNPs detection of Bam HI digested genomic DNA 
for 14 M. tuberculosis clinical specimens 
AuNPs detection of Bam HI digested genomic DNA was done using species specific 
oligo-targeter only. Genomic DNA was denatured (95 °C, 3 min) and allowed to 
anneal (48 °C, 1 min) with species specific oligo-targeter. This second version of the 
assay confirmed the nano-gold assay sensitivity. Negative control (upper row, far left 
tube) with Mycobacterium smegmatis digested genomic DNA. Tubes 11 to 24: M. 









Figure 28. Absorption spectra of AuNPs in samples containing mycobacteria 
digested genomic DNA 
The suspected sample denatured and annealed with oligo-targeters in the presence of 
salt. AuNPs were added for detection. In negative specimen, the target DNA did not 
hybridize with specific oligo-targeters. Oligo-targeters uncoil sufficiently to get 
adsorbed on negatively surface charged AuNPs through nitrogenous bases. AuNPs 
stabilization occurs in the presence of salt, preventing their aggregation and 
absorbance peak shift. In positive specimens, the target DNA hybridized with specific 
oligo-targeters. AuNPs aggregated change their visual color from red to blue shifting 

























Figure 29. Nano-gold assay detection limit for Mycobacterium H37Ra PCR 
amplicons 
Mycobacterium H37Ra amplicons were serially diluted and tested by the TB 
nanogold assay. The ability of the oligo-targeter to find the target decreased by 
increasing dilution. AuNPs induced complete aggregation in the first 3 reactions (R1-
R3), partial aggregation in R4 and R5 reactions, and no aggregation in the last 
reaction (R6). R1-R6: Mycobacterium H37Ra samples contain amplified DNA with 
different DNA quantities: (R1) 14 ng, (R2) 7 ng, (R3) 3.5 ng, (R4) 1.75 ng, (R5) 


















Figure 30. Nano-gold assay detection limit for mycobacterium digested genomic 
DNA from clinical strains 
Digested genomic DNA detection limit for Mycobacterium tuberculosis clinical 
specimen. Mycobacterium genomic DNA was serially diluted and allowed for 
detection. The first reaction was positive while the rest of dilutions gave negative 
aggregation. (C) Negative control. (3) Mycobacterium tuberculosis clinical strain 




















Figure 31. Detection principle of unmodified gold nanoparticles 
In unmodified AuNPs detection, DNA is denatured and annealed to specific oligo-
targeters. The hybridization buffer mostly includes salts. Then AuNPs are added to 
the reaction mixture. (A) In the presence of positive target, oligo-targeters hybridize 
and become unavailable to protect and stabilize AuNPs. Presence of salt causes 
AuNPs to aggregate and the solution changes from red to blue. (B) In the presence of 
no or non-specific target, oligo-targeters uncoil and get adsorbed via their nitrogenous 
base side to the negatively charged AuNP surface. AuNPs become stabilized and do 
not aggregate; solution color remains red.    
 









Figure 32. Possible hypothetical explanations for the use of a single, rather than 
two, oligo-targeter in the TB nano-gold assay  
Gold nanoparticles detection principle contradicts with using single oligo-targeter. (A) 
The first possible explanation is that long (target) ssDNA do not stabilize AuNPs. 
AuNPs induced aggregation changing their visual color from red to blue. (B) The 
second probable explanation is that DNA target may denatures and/or anneals in a 
replication bubble manner. Thus, the presence of one/two oligo-targeter/s to anneal 
with the target in a replication fork would not stabilize AuNPs allowing for their salt-
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